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Tuberculosis vaccine candidates based on mycobacterial cell envelope components. 1 
Abstract 2 
Even after decades searching for a new and more effective vaccine against tuberculosis, the scientific community is 3 
still pursuing this goal due to the complexity of its causative agent, Mycobacterium tuberculosis (Mtb). Mtb is a 4 
microorganism with a robust variety of survival mechanisms that allow it to remain in the host for years. The structure 5 
and nature of the Mtb envelope play a leading role in its resistance and survival. Mtb has a perfect machinery that 6 
allows it to modulate the immune response in its favor and to adapt to the host’s environmental conditions in order to 7 
remain alive until the moment to reactivate its normal growing state. Mtb cell envelope protein, carbohydrate and lipid 8 
components have been the subject of interest for developing new vaccines because most of them are responsible for 9 
the pathogenicity and virulence of the bacteria. Many indirect evidences, mainly derived from the use of monoclonal 10 
antibodies, support the potential protective role of Mtb envelope components. Subunit and DNA vaccines, lipid 11 
extracts, liposomes and membrane vesicle formulations are some examples of technologies used, with encouraging 12 
results, to evaluate the potential of these antigens in the protective response against Mtb.  13 
Keywords: vesicles, cell wall, membrane, vaccines, Mycobacterium tuberculosis 14 
1.0. Introduction 15 
Despite establishing Mycobacterium tuberculosis (Mtb) as the causative agent for tuberculosis (TB) and the 16 
availability of a live vaccine for its prevention since the beginning of the past century, the disease continues to claim 17 
more than a million lives each year (1, 2).  18 
Bacille Calmette Guerin (BCG), the current vaccine against TB protects against miliary and meningeal TB in children 19 
but its protection against pulmonary TB (PTB) in adults is questionable. The pulmonary form of the disease is the 20 
most common form and is primarily responsible for disease transmission (3-5). BCG generally show high and 21 
consistent efficacy in the developed world, but in contrast, its effect in developing countries has been far from 22 
successful (3-5). 23 
Mtb uses diverse strategies to survive in a variety of host environments and to evade the host´s immune response 24 
(IR) (2). The nature of Mtb envelope confers to the bacilli strong resistance to degradation by host enzymes, 25 
impermeability to toxic macromolecules and extreme hydrophobicity (6, 7). Molecules expressed on the 26 
mycobacterial cell envelope (CE) mediate the interactions between Mtb and the host, its recognition by host cell 27 
receptors is crucial to influence the type of the ensuing innate immune response, which will in turn determine the 28 
subsequent specific immune response against the bacteria (6, 7). 29 
Considering the relevant role of the CE in the infection process and its outcome, the use of its components as 30 
adjuvants and/or targets for vaccine development has dominated the efforts for the development of new generation 31 
vaccines against TB (8). In this review, we will discuss on Mtb CE components (CEC) and their potential for the 32 
development of new vaccine candidates (VCs). 33 
2.0. Mtb CE. Structural organization and components. 34 
Mtb CE is a complex structure, formed by three main layers: 1) capsule, 2) cell wall (CW) and, 3) plasmatic 35 















About 40% of the CE dry mass is represented by lipids (10), and 90% of the subclasses of mycobacterial lipids are 37 
molecularly distinct from humans and other prokaryotes (7, 11). This unique CE composition and organization is 38 
believed to render mycobacteria less susceptible than other bacterial pathogens to various antibiotic classes, and 39 
provide protection against oxidative radicals and desiccation resistance, in addition to the possibility to manipulate 40 
the host immune system (12-14). 41 
2.1. Capsule. Mtb capsule is an external carbohydrate-enriched layer that contains proteins, polysaccharides and 42 
low quantity of lipids (9). It confers protection to mycobacteria against several external factors, such as 43 
antimicrobial agents, and has a direct interaction with the elements of the IR (6, 7, 9-15). The proteins 44 
embedded in the capsule are involved in the synthesis and maintenance of the CE, and together with some of 45 
the capsular glycans, are responsible for adhesion, penetration, infection and survival of mycobacteria in the 46 
host cells (16). The capsule also serves as a passive barrier by impeding the diffusion of macromolecules 47 
towards the inner parts of the envelope (16). Additionally, secreted enzymes are identified which are potentially 48 
associated with the detoxification of reactive oxygen intermediates such as catalase/peroxidase and superoxide 49 
dismutase, related with the active resistance of the mycobacteria to the host´s microbicidal mechanisms (16). In 50 
addition, some toxic lipids, lytic substances and capsular constituents causes immunopathology during Mtb 51 
infection by inhibiting both macrophage-priming and lymphoproliferation (16).  52 
Stokes and colleagues demonstrated that the capsule of the Mtb family members could limit the interaction of 53 
the bacteria with macrophages in the absence of serum opsonins, thereby reducing and/or regulating the uptake 54 
of bacteria by the phagocytes (17). A previous study with a Mtb strain mutated in the polyketide synthase gene 55 
msl3 with deficit in lipoglycans diacyltrehalose and polyacyltrehalose, showed alteration in the attachment of the 56 
capsule of the mutant (18). 57 
Two of the most abundant components of the Mtb capsule are the 19-kDa glycoprotein and the antigen 85 58 
complex (19). The 19-kDa secreted lipoglycoprotein (Rv3763; LpqH) is an abundantly expressed CE-associated 59 
and secreted glycolipoprotein (20). Henao-Tamayo et al, showed that the 19-kDa lipoprotein is essential for the 60 
replication of Mtb in the lungs of normal and immunocompromised mice in an aerosol infection model, while 61 
mutant Mtb, which lacks the protein, allows the bacilli to persist as a low-grade chronic infection (21). On the 62 
other hand, the Ag85 complex which includes three proteins: Ag85A (31-kDa), Ag85B or α-antigen (30-kDa), 63 
and Ag85C (31.5-kDa), represent the most common Mtb proteins secreted into culture fluids (22). The role of 64 
the Ag85 complex in the pathogenesis and virulence of Mtb is widely studied and the main described 65 
mechanisms include binding to fibronectin and inhibition of phagosome maturation in macrophages (22). 66 
2.2. Cell Wall. Mtb CW is different from other prokaryotes as it is composed of two segments, i.e. upper (outer 67 
membrane) and lower (CW core). The lower segment functions as a central axis, integrated by peptidoglycans 68 
covalently attached to arabinogalactan via phosphoryl-N-acetyl-glucosaminosyl-rhamnosyl linkage, which in turn 69 
esterified to mycolic acids (α-alkyl, β-hydroxy long chain fatty acids) and formed mycolyl arabinogalactan-70 
peptidoglycan (mAGP), better known as the CW core (6). While the upper segment (outer membrane) 71 
comprises free lipids, proteins, phosphatidylinositol mannosides (PIMs), phthiocerol-containing lipids, 72 
















Previous studies showed that PIMs, LM and LAM have potent immunomodulatory and immunopathogenic 75 
activities during mycobacterial phagocytosis, macrophage activation and macrophage microbicidal mechanisms 76 
via regulation of cytokine production and secretion. Due to its high solubility, these lipids and proteins are 77 
important molecules for signaling during disease, while the insoluble CW core is important to maintain cell 78 
viability and a robust basal structure supporting the outer “myco-membrane” (outer membrane) (6, 25). This 79 
outer membrane is especially hydrophobic since it is rich in mycolic acids, phospholipids and cord-factor (12). 80 
The so-called “cord-factors” are the best-known mycolic acids esters in mycobacteria, principally trehalose-6,6-81 
dimycolate (TDM) and trehalose monomycolate (TMM) (26). 82 
TDM is the most abundant lipid released by Mtb, which have multiple functions in the pathogenesis of primary, 83 
secondary and cavitary TB (27). In primary TB, TDM interacts with lipids within granulomas to form caseating 84 
granulomas and in secondary TB, the accumulation of mycobacterial Ags and host lipids in alveoli promotes the 85 
activation of toxicity and antigenicity of TDM which rapidly leads to caseation necrosis and formation of cavities 86 
(27). TDM hinder the elicitation of an effective IR through the promotion of a detrimental pro-inflammatory 87 
cytokine production, the persistence of the mycobacteria inside macrophages and retarding the phagosome 88 
maturation (21). Phthiocerol dimycocerosates (PDIMs) are the most abundant mycobacterial lipids, which is 89 
non-covalently attached to the CW skeleton (10). They are the only non-amphipathic lipids produced by this 90 
organism and they play an important structural role in providing a stable base for insertion of other lipids (10). 91 
They could also act as a fluidity modifier, modulating the CW viscosity (28). Thus, PDIMs may affect the 92 
organization of the host membrane which favor receptor-mediated-phagocytosis of Mtb and prevent the 93 
phagosomal acidification which enable Mtb to survive in a protective niche (29). The escape of Mtb from the 94 
phagosome has been postulated to be linked to the presence of PDIMs which induce cell necrosis and Mtb 95 
dissemination (30). Across the CW there are embedded proteins which are abundantly expressed in Mtb and 96 
associated with the other components of this structure, e.g. the 19 kDa lipoprotein and 71 kDa protein which 97 
have been studied as potential VCs for TB (8, 31). Overall, the unusually high mycolic acid content, together 98 
with a variety of cell surface polysaccharides and other intercalated lipids such as sulfolipids (SLs) contribute to 99 
the wall’s limited permeability, it’s virulence and resistance to therapeutic agents (7, 28).  100 
The CW of Mtb is a well-equipped frame that protects this pathogen from unfavorable environments (32). 101 
Peptidoglycan is a complex polymer described as essential component of the bacterial CW (33). Recently, the 102 
role of two enzymes, RodA and PbpA, which are required for the structural shape of Mtb peptidoglycan were 103 
elucidated (33). Both enzymes are required for regulating cell length, without affecting mycobacterial growth and 104 
in the guinea pig infection model, RodA and PbpA are also essential for bacterial survival and formation of 105 
granuloma, suggesting that these proteins may be involved in virulence and as a consequence, in the survival of 106 
Mtb inside the host (33). 107 
Mtb is a pathogen characterized by the export of large quantities of proteins during its growing process. One of 108 
the major extracellular proteins is the glutamine synthetase, an enzyme related with the presence of a poly-L-109 
glutamate component in the CW (34). Since poly-L-glutamate is absent in non-pathogenic mycobacteria (35), 110 
the presence of glutamine synthetase has been suggested to be important in mycobacterial virulence. (34), 111 
The α/β hydrolases constitute a powerful family of enzymes in Mtb associated with lipid metabolism, with their 112 
key role in the biosynthesis and maintenance of the pathogen’s CE. They have also been associated with Mtb 113 















and latency (36). A cholesterol ring-cleaving hydrolase, IpdAB, is an important virulence factor implicated in Mtb 115 
pathogenesis (37) since the virulence and persistence of this pathogen is related to its ability to degrade host-116 
derived lipids, including cholesterol (37). IpdAB is also essential for Mtb growth in macrophages based on 117 
transposon mapping (38) and through using deletion mutants of the enzyme (39). 118 
LytR-CpsA-Psr (LCP) is a protein domain with an important role on bacterial CW synthesis, specifically related 119 
to the transference of arabinogalactan to peptidoglycan. In a previous study using single mutants in the genes 120 
encoding these Mtb proteins, it was demonstrated that these genes are important for mycobacterial growth and 121 
antibiotic susceptibility (40).  122 
Hydrolase Important for Pathogenesis-1 (Hip1) is another CW related protein with an important function on Mtb 123 
virulence (41). The catalytic activity of Hip1 on the host IR was demonstrated using a Hip1-knockout strain, 124 
which induced an increased proinflammatory response in both macrophages and neutrophils compared to the 125 
wild type (42). 126 
2.3. Plasmatic membrane. Plasmatic membrane, also known as cytoplasmic membrane, is composed of a 127 
phospholipid bilayer containing cardiolipin, phosphatidylethanolamine and phosphatidylinositol, which is similar 128 
to the rest of prokaryotes. However, in mycobacteria the phospholipid derivatives are highly glycosylated (9). 129 
Mtb can be distinguished by a genus-specific, C19 fatty acid, known as tuberculostearic acid (15). It appears 130 
that the mycobacterial plasmatic membrane plays a limited role in pathogenicity and its main function is 131 
maintenance of the influx-efflux equilibrium (11, 16). 132 
3.0. Role of Mtb CE in virulence 133 
Mtb CEC constitute the major determinants of mycobacterial virulence. Being present at the interface between the 134 
microorganism and the host, the components of the mycobacterial CE are responsible in targeting host–pathogen 135 
interactions (43). The expression of genetic determinants involved in the interaction between the microorganism and 136 
the host, have been demonstrated to influence the ability of a bacterial pathogen to survive inside the host (44). This 137 
mechanism results in the possibility of pathogens to resist physiological and environmental stress (44). The virulence 138 
of Mtb also depends on the genes responsible for the processes of biosynthesis, degradation and transport of the CE 139 
(45). 140 
There are many virulence factors which have evolved in the Mtb complex members as a response to the IR (45). The 141 
CE contains unique lipids and glycolipids that render extreme hydrophobicity to the outer surface. These lipids which 142 
include mycolic acids, phosphatidyl inositol mannosides, PDIMs and lipoglycans such as LM and LAM play important 143 
roles in maintaining integrity of the CE and are involved in the pathogenicity of mycobacteria (46, 47). 144 
Mycolic acids are the hallmark of the CE of Mtb which create a special lipid barrier with their perpendicular orientation 145 
relative to the plane of the membrane (6). These components affect the permeability of the CE and the ability of Mtb 146 
to form biofilms (48). Furthermore, it is essential for the survival of mycobacteria and promote the pathogenicity 147 
during infection (49). Different studies have reported that the disruption of the mycolic acids synthesis pathway or 148 
alteration of their structure, affect the virulence of mycobacteria (50). 149 
LAM is a major virulence factor associated with Mtb since it allows the mycobacteria to survive in the host cell 150 
environment by altering host resistance and IR (51). LAM inhibits phagosomal maturation in the host cell and 151 















TDM or cord factor is another virulence factor produced abundantly in virulent strains of Mtb (27, 56, 57). TDM blocks 153 
the phagosome-lysosome fusion and migration of polymorphonuclear neutrophils (27, 56, 57). It contributes to the 154 
maintenance of the granulomatous response and the long term survival of Mtb in host cells (27, 56, 57). 155 
Accumulation of TDM causes weight loss in the host, resulting in the condition known as cachexia (58). The 156 
cyclopropane modification of TDM in virulent Mtb strains increase the inflammatory activity upon Mtb recognition by 157 
effectors of the innate IR, promoting the Mtb virulence through the manipulation of immune activation (59).  158 
Previous studies showed that PDIM of Mtb are involved in macrophage invasion, inducing changes in the 159 
organization of plasma membrane lipids (6, 29, 30). Regarding other components of the Mtb CE, the production of 160 
phenolic glycolipids in Mtb is associated with the hyper-virulent phenotype displayed by a subset of Mtb isolates. 161 
There is also a clear correlation between the presence of sulfolipids in Mtb isolates and virulence in guinea pigs (60, 162 
61).  163 
4.0. Indirect evidences of the protective role of Mtb CEC 164 
Studies with polyclonal (pAbs) and monoclonal antibodies (mAbs), which challenged the traditional dogma of the 165 
exclusive role of cellular immunity in the defense against Mtb, had been very important in providing indirect evidence 166 
of the potential role of Mtb CEC in the protection against Mtb (62). 167 
The first study describing a beneficial effect of the administration of mAbs directed to mycobacterial CEC on the 168 
course of Mtb infection was conducted with the mAb 9d8 (IgG3) that recognizes AM exclusively (63). This mAb, 169 
increased the survival of intratracheally-infected mice when the Mtb Erdman strain was pre-coated with it. In this 170 
study, the positive effect on survival was associated with an enhanced granulomatous response in the lungs as 171 
compared to controls receiving an isotype-specific non-related mAb (63). 172 
Another mAb, MBS43 (IgG2b) directed to MPB83, a surface lipoglycoprotein, prolonged the survival of intravenously 173 
infected mice associated with reduced granuloma size and decreased necrosis in the lung (64).  174 
Enhanced survival has also been observed in experiments using the mAb SMITB14 (IgG1) directed against the AM 175 
portion of LAM. Passive immunization of BALB/c mice with SMITB14 and its corresponding F(ab') have been shown 176 
to provide protection against Mtb infection in BALB/c mice, as determined by dose-dependent reduction in bacterial 177 
load in lungs and spleens, reduced weight loss and increased long-term survival (65). 178 
In another study, mice receiving intravenous mAb 5c11 (IgM), that recognizes other mycobacterial arabinose-179 
containing carbohydrates in addition to AM, prior to mannosylated lipoarabinomannan (ManLAM) administration, 180 
showed a significant clearance of ManLAM and redirection of this Mtb product to the hepatobiliary system (66). This 181 
study provided evidence that Abs can affect the fate of free mycobacterial polysaccharides. In addition, it was 182 
suggested that the liver and bile salts may have a role in the defense against mycobacterial infection, especially in 183 
the presence of specific Abs (66). 184 
Heparin-binding haemagglutinin (HBHA) is a surface exposed protein which has been involved in mycobacterial 185 
dissemination (67). Two mAbs against HBHA: 3921E4 (IgG2a), and 4057D2 (IgG3), were used to coat mycobacteria 186 
before administration to mice. In mice receiving mycobacteria pre-coated with either mAb, spleen CFUs were 187 
reduced while lung CFUs were comparable to those of control (67). These results suggested that anti-HBHA Abs 188 
interfered with mycobacterial dissemination. 189 
The Mtb 16 kDa protein (also called Acr antigen or HspX) has been identified as a major membrane protein and its 190 















the respiratory fluids after its administration by different routes (71). Intranasal administration of mAb TBA61 (IgA), 192 
directed against 16-kDa antigen of Mtb resulted in lung CFU reduction 9 days after intranasal or aerosol challenge 193 
with Mtb (72). These results suggested that Abs could affect the early stages of infection. In another series of 194 
studies, López and colleagues evaluated the efficacy of TBA61 in the control of pulmonary infection (73). Using an 195 
intratracheal model of pulmonary infection with Mtb H37Rv, they evaluated bacterial load and morphometric and 196 
histological changes in the lungs of infected mice treated with the mAb (73). The results showed a significant 197 
reduction in bacterial load and morphometric and histopathological changes in lungs of mice treated with TBA61, 198 
compared to control groups. The reduction of CFU in lungs of the treated group was associated with a better 199 
organization of the granulomas and less pneumonic area (73).  200 
Balu and colleagues evaluated the properties of a new human mAb recognizing the 16 kDa protein (74). The mAb 201 
2E9 (IgA1) was constructed using a single-chain variable fragment clone selected from an Ab phage library (74). The 202 
intranasal co-inoculation of 2E9 (IgA1) with recombinant murine IFN-γ significantly inhibited lung infection in 203 
transgenic mice for human myeloid IgA Fc receptor, CD89 (74). Inhibition of the infection by the Ab was synergistic 204 
with human rIFN-γ in cultures of purified human monocytes (74). This study demonstrated the feasibility of 205 
generating human mAbs to mycobacterial Ags, and their efficacy in mouse models adapted to human immune 206 
system (74). 207 
In other experiments, the coating of Mtb with human IgG and secretory IgA formulations inhibited the infection in 208 
mouse models of progressive TB, which suggest that human Abs, directed to CEC are associated with protection 209 
against Mtb (75, 76). 210 
The administration to mice of pAbs derived from healthy humans highly exposed to Mtb afforded protection in a Mtb 211 
challenge model in mice with the protection being associated with the presence of Abs against the CE (77). 212 
Administration of a commercial human IgG formulation pre-incubated with Mtb, abrogated the initial protection 213 
afforded by this formulation, suggesting an important role of Abs in Mtb protection (76). 214 
These experimental evidences suggest a role of Abs in the defense against TB and the importance to consider the 215 
potential of mycobacterial CEC to elicit protective Ab responses in TB vaccine development. 216 
5.0. TB VCs based on mycobacterial CEC 217 
CEC have been used in TB vaccine development as adjuvants, and/or vaccine immunogens, although it is not 218 
always possible to establish a clear-cut distinction of these activities due to the overlapping effects of the 219 
components in several VCs. In the following sections, we will discuss the use of different CEC as adjuvants and 220 
vaccine immunogens.  221 
5.1.  Mycobacterial CEC as adjuvants. Vaccines based on individual proteins or fusion proteins are attractive 222 
alternatives because they are safe and produce little or no adverse effects. However, with few exceptions, proteins 223 
themselves are not detected as signs of danger and therefore do not induce IR in their first encounter with the host. 224 
To induce an IR, protein vaccines require pathogen-associated molecular patterns (PAMPs), which are small 225 
molecular structures found mainly in microorganisms like bacteria and viruses. The recognition of PAMPs through 226 
the pattern recognition receptors (PRR) triggers the induction of innate responses that finally lead to the specific 227 
adaptive IR against protein vaccines.  228 
The immune properties of the lipid PAMPs present in the CE of mycobacteria have been extensively investigated. 229 















mycobacterial CW extracts in different vaccine formulations against TB (Table 4) and other diseases (81, 82), 231 
including cancer (83, 84). Further studies have shown that lipids present in the CE of mycobacteria are powerful 232 
adjuvant for Th1 IR when delivered as liposomes and that these lipids can improve the protection against TB by 233 
themselves (85) (Table 4) or in a formulation with a subunit vaccine (86) (Table 1). 234 
LMs, LAMs, ManLAM, lipoproteins, PDIMs, mycolic acids (MAs) and mycolate esters are among the most important 235 
PAMPs on the mycobacterial CE. In recent years, much progress has been made in elucidating the immune 236 
molecular mechanisms triggered by mycobacterial glycolipids and the host cellular receptors involved in these 237 
processes (87). However, a few studies have demonstrated the contribution of these glycolipids (or their derivatives) 238 
to the protection against Mtb in animal models, when formulated with subunit vaccines.  239 
Below, we describe examples that have been reported on the use of mycobacterial CEC as adjuvants of TB subunit 240 
VCs in Mtb-challenge experiments. 241 
5.1.1. Monomycoloyl glycerol (MMG): The study of Andersen et al. has demonstrated that immunization of 242 
mice with Ag85B/ESAT-6 adjuvanted with N,N-dimethyl-N,N-dioctadecylammonium bromide (DDA) 243 
liposomes in combination with MMG or synthetic analogues induced a Th1-biased IR that provided 244 
significant protection against TB at levels comparable to the protective immunity induced by BCG 245 
vaccination (88) (Table 1). 246 
5.1.2. TDM: TDM is one of the most potent immunostimulatory molecules on the mycobacterial CE; this glycolipid 247 
formulated with either protein Ags or DNA vaccines has shown powerful adjuvant properties.  248 
The study of de Paula et al., has shown that a single dose of co-encapsulated DNAhsp65 and TDM into 249 
biodegradable poly (DL-lactide-co-glycolide) (PLGA) microspheres reduced the bacterial burden of Mtb 250 
in mice and guinea pigs as efficiently as three doses of naked DNAhsp65 (89) (Table 2). However, this 251 
vaccination scheme did not exceed the protection conferred by BCG. Conversely, boosting BCG-252 
vaccinated mice with DNAapa coencapsulated with TDM in microspheres reduced the bacterial burden 253 
in lungs 70 days post Mtb challenge compared to vaccination with BCG alone (90) (Table 2). 254 
Mtb10.4–HspX fusion antigen adjuvated with DDA and TDM induced antigen-specific humoral and cell-255 
mediated immunity. When used as a booster to BCG, this formulation slightly improved the protection 256 
conferred by BCG alone against Mtb challenge in mice (91) (Table 1). 257 
Similarly, Decout et al. found that vaccination of mice with Ag85A and TDM incorporated in DDA 258 
liposomes induced strong Th1 and Th17 IRs and conferred protection against Mtb infection (92) (Table 259 
1). 260 
The toxicity of TDM restricts its use as adjuvant for vaccines. Unlike TDM, trehalose dibehenate (TDB), 261 
a structural analogue of TDM, in which simpler fatty acids replace the complex mycolic acids, has an 262 
acceptable toxicity. Several studies have demonstrated that TDB formulated in cationic liposomes with 263 
DDA (formulation called CAF01) and with a fusion protein Ag85B-ESAT-6 or ESAT-6 as single protein 264 
induced strong Th1 and Th17 responses and protection against Mtb infection in mice at levels 265 
comparable to the protective immunity induced by BCG vaccination (93-95) (Table 1). 266 
The adjuvant properties of CAF01 and two other liposomal adjuvants: Cationic CAF04 (DDA/MMG), 267 
and CAF05 [DDA/TDB in /poly(I:C)] have been tested in combination with the fusion protein H56 268 















immunization with formulations of H56 in all adjuvants (used as BCG-boosters) resulted in better 270 
survival of the monkeys infected with Mtb and better protection readouts compared to BCG alone, 271 
albeit at non-significant levels (96) (Table 1). 272 
5.1.3. Glucose monomycolate: The study of Decout et al., has demonstrated that glucose and mannose 273 
esterified at O-6 by a synthetic α-ramified 32-carbon fatty acid are agonists of the C-type lectin receptor 274 
Mincle with similar adjuvant activity to that of TDM. One of these structurally simple synthetic Mincle 275 
ligands, GlcC14C18, has been shown to be less toxic than TDB on the host cells. This adjuvant 276 
induced protective immunity in a mouse model of Mtb infection when incorporated in DDA and 277 
inoculated with Ag85A to a similar extent to that afforded by vaccination with Ag85A/DDA/TDB (92) 278 
(Table 1). 279 
5.1.4. Arabinomannan (AM): The portion of AM of LAM has been used as adjuvant in different vaccine 280 
formulations. When AM linked to Ag85B was conjugated in Eurocine™ L3 adjuvant emulsion or in 281 
Alum, the resulting conjugates showed good protective efficacy against Mtb challenge in guinea pigs 282 
and mice, respectively. However, the protection afforded by these conjugate vaccines in mice was less 283 
efficient than BCG vaccination (97) (Table 1). An AM-tetanus toxoid conjugate (AM-TT), formulated in 284 
Eurocine™ L3 adjuvant, was used as intranasal boost to BCG. The bacterial loads in the spleens of 285 
Mtb-challenged animals were reduced in boosted animals compared to non-boosted animals. This 286 
finding suggests a direct contribution of AM to the protective efficacy of the conjugate vaccine. 287 
However, lung protection against Mtb infection was not improved in boosted animals (98) (Table 1).  288 
Finally, Prados-Rosales et al.; have used the native capsular AM in vaccine formulations against 289 
tuberculosis infection of mice. They found that vaccination with capsular AM-Ag85b conjugate 290 
increased the survival of Mtb infected animals when compared to non-vaccinated or Ag85b-immunized 291 
mice. The survival of AM-Ag85b-vaccinated mice was similar to that of BCG-vaccinated animals but 292 
the bacterial counts in the lungs and spleen of mice after Mtb challenge was similar between the three 293 
groups (99) (Table 1). Interestingly, the authors of this study used passive immunization of naïve mice 294 
with sera from AM-Ag85b vaccinated animals to demonstrate that the protection mechanism induced 295 
by AM-Ag85b was antibody (Ab) mediated. They propose that specific Abs to both AM and Ag85b 296 
contributed to control bacterial dissemination. This observation is consistent with the modest 297 
protection conferred by AM-conjugates linked to Mtb unrelated proteins, such as TT [see above, (98) 298 
(Table 1)] and PA from Bacillus anthracis (99) (Table 1). 299 
5.1.5. Phosphatidylinositol di-mannoside (PIM2): PIM2 and its derivatives have been formulated with the 300 
fusion protein Ag85A-ESAT-6 and tested as anti-bovine TB vaccines in a mouse model. Vaccination of 301 
mice with Ag85A-ESAT-6+ PIM2 or BCG conferred a significant reduction in the bacterial load in lungs 302 
compared to that for the PBS control, but only BCG vaccination resulted in a significant reduction in the 303 
mean spleen bacterial count. Other PIM2 derivatives were not shown to improve the protection induced 304 
by the fusion protein Ag85A-ESAT-6 alone. In fact, PIM2ME, a monoether derivative of PIM2, 305 
appeared to have a detrimental effect in the control of bacterial replication in lungs and spleen of 306 
vaccinated and Mycobacterium bovis (Mbo) infected mice (100) (Table 1). Larrouy-Maumus et al., 307 















sulfoglycolipids (Ac2SGL) in liposomes made of DDA and TDB and used them as vaccines against Mtb 309 
in guinea pigs. The results showed that lipid VCs induced reduction of bacterial counts in spleen but 310 
not in lungs when compared to the unvaccinated group. However, vaccinated animals showed less 311 
pathology and also less lung necrosis (101) (Table 1).  312 
Wedlock et al., used culture filtrate proteins (CFPs) from Mbo with different lipid formulations in DDA as 313 
boosts of BCG vaccination in cattle. In this study, PIM2 did not improve the protection induced by BCG 314 
alone in Mbo-challenged cattle. Remarkably, only the synthetic lipopeptide and the TLR2 agonist, 315 
Pam3Cys-SKKKK, formulated in DDA with CFPs conferred better protection compared to BCG alone 316 
(102) (Table 1). 317 
5.1.6. Poly-α-L-glutamine (PLG) are glutamine-rich self-assembling peptides that are associated with the 318 
peptidoglycan layer of mycobacteria through noncovalent interactions. The adjuvant power of these 319 
peptides has been recently assessed. PLG improved the protective efficacy of ESAT-6 alone in a 320 
mouse model of TB, thus reaching to a protection level equivalent to that conferred by BCG vaccination 321 
(103) (Table 1).  322 
5.2. Mycobacterial CEC as immunogens. Vaccines obtained from/or containing CEC can be classified according to 323 
the platform strategy: either as subunits, DNA, Mtb Ags expressed in attenuated vectors, CE extracts and natural and 324 
artificial membrane vesicles (MVs) (Tables 1-5).  325 
5.2.1. Subunits. Considering the potential for protection of the Ab responses against CE carbohydrates, and the 326 
growing evidence of the importance of the lipid components in the elicitation of potent T cell responses 327 
against mycobacterial lipids, the breadth of the evaluated VCs as subunits has been expanded beyond the 328 
classical protein-based vaccine targets including carbohydrate and lipid components (Table 1) (63, 65, 329 
104-107). 330 
Various subunit VCs have been evaluated using different adjuvant and delivery systems, as isolated 331 
components or as cocktails or fusion proteins, as multi-stage constructions covering different stages of the 332 
infection, administered by different routes and in prime-boost regimes, combined with BCG or with other 333 
VCs (Table 1). 334 
In general, the VCs evaluated showed good potential as TB vaccines inducing good immunogenic 335 
responses and protection against Mtb or Mbo in animal models, some of them are at the advanced stages 336 
of clinical evaluation (Table 1). 337 
 338 
5.2.2. DNA. DNA vaccines, with their capacity to elicit humoral and cellular Th1 IRs, including CD8+ cytotoxic 339 
responses have been considered obvious candidates for new generation TB vaccine development (154, 340 
155). 341 
DNA VCs, containing CE Ags genes, with different adjuvants, delivery systems and prime-boost schemes 342 
demonstrated good immunogenicity and protective capacity in different animal models (Table 2).  343 
5.2.3. Mtb CE-antigens expressed in attenuated vectors. The use of bacterial and viral vectors expressing 344 
heterologous Ags as new generation vaccines is one of the most important technological platforms due to 345 















themselves or combined with other VCs in prime-boost schedules, exemplify some of the candidates at the 347 
advanced stages of clinical evaluation (Table 3). 348 
5.2.4. CE extracts. The presence in the mycobacterial CE of multiple components associated with the interaction 349 
with host receptors, virulence and important processes of relevant importance for the survival of the 350 
bacteria, in addition to their accessibility to the host IRs, has influenced the use of different CE extracts as 351 
experimental VCs (Table 4). 352 
These candidates represent multi-antigenic formulations with intrinsic adjuvant effect, which has been 353 
evaluated as prophylactic and/ or therapeutic experimental vaccines in different animal models and clinical 354 
trials (Table 4). 355 
5.2.5. Natural and artificial membrane vesicles (MVs). The important role of bacterial MVs in cell–cell 356 
communication, immunomodulation, virulence and cell survival, and their intrinsic potential advantages as 357 
VCs have focused the interest for their evaluation in animal and human studies, some of them 358 
demonstrating suitable efficacy (230, 231). 359 
Mtb produce MVs, which contain relevant Ags and are potentially involved in the virulence and in the 360 
interaction with immune effectors inducing different types of IRs (232-234). 361 
Considering the results obtained with the evaluation of MVs as vaccines from different microorganisms, 362 
natural and artificial MVs from pathogenic and non-pathogenic mycobacteria have been evaluated in 363 
animal models demonstrating their immunogenicity and protective capacity, either used alone or as BCG 364 
boosters (Table 5). 365 
6. Concluding remarks 366 
Mtb CE is a structure which have been capitalized as an important part of the research related to Mtb due to its 367 
peculiar structural organization and its huge impact in the physiology, survival, virulence, interactions with the host 368 
cells and the immune system and its potential importance in diagnosis, therapeutic and vaccine development (6-9, 369 
12, 15, 16). 370 
The great diversity and accessibility of their components comprising proteins, lipids, carbohydrates, glycolipids and 371 
lipoproteins make them potential targets for vaccine development (238-242). 372 
The important contribution of the CEC in the interaction with the host and the elicitation of non-specific IRs, 373 
associated with their intrinsic adjuvant properties have attracted attention in the field of vaccine development (6, 15, 374 
243-246). 375 
Considering the growing evidence of the importance of the Ab responses in the protection against Mtb, the selection 376 
of accessible CEC as VCs is an obvious choice with encouraging results (62, 97-99). 377 
The presence of immunodominant protein Ags, eliciting protective IRs in the acute phase of the infection highlights 378 
the interest in the CEC, as exemplified by the incorporation of this class of Ags in various vaccine platforms 379 
evaluated either in animal models or clinical evaluation (111, 140, 141, 157, 159, 174, 178, 179, 188, 190, 202, 216, 380 
217).  381 
The importance of lipid components in the induction of specific IRs with potential impact in protection also present an 382 
added element which demonstrate the importance of CEC for the development of new generation vaccines against 383 















The great variety of Ags included in the CE related with different stages of the infection is an added advantage for the 385 
development of multi-stage VCs such as fusion proteins, antigen cocktails, CE extracts and natural and artificial 386 
membrane vesicles, which have been evaluated successfully in animal models, with some under clinical evaluation 387 
(69, 85, 109, 113, 130-132, 134, 136, 223-228, 235-237). 388 
Another aspect that needs to be considered is the complexities involved in advancing some VCs (extracts synthetic 389 
analogues or combinations) from preclinical to clinical proof of concept. The main potential hurdles that face these 390 
VCs are associated with the characterization of the active component, complexity & consistency of manufacturing 391 
processes and the associated challenges in quality control issues of manufacturing. 392 
It is interesting to note that apart from whole cell-based VCs, almost all the VCs which have been evaluated and 393 
those under evaluation in animal models and in clinical trials belong to the Mtb CEC (3, 248). However, it should be 394 
highlighted that the CE based VCs studied thus far, only represent a fraction of the great diversity of the CEC 395 
(proteins, lipids and carbohydrates) that are available (239, 243, 249, 250). Many others have the potential to be 396 
further explored as new components for the development of vaccines stimulating all the components of the IR and 397 
targeting all the phases of the infection. 398 
Acknowledgements 399 
This work was supported by the LRGS Grant, (203/PPSK/ 67212002), Ministry of Education Malaysia. 400 
Conflict of interest 401 
The authors declare that they have no competing interest. 402 
Reference 403 
1. World Health Organization. Global tuberculosis report 2017. Geneva: WHO; 2017. WHO/HTM/TB/2017.23. 404 
Retrieved November 2017 from http://apps. who. int/iris/bitstream/10665/259366/1/9789241565516-eng. 405 
pdf; 2017. 406 
2. Chai Q, Zhang Y, Liu CH. Mycobacterium tuberculosis: An Adaptable Pathogen Associated With Multiple 407 
Human Diseases. Frontiers in cellular and infection microbiology. 2018;8. 408 
3. Zhu B, Dockrell HM, Ottenhoff TH, Evans TG, Zhang Y. Tuberculosis vaccines: Opportunities and 409 
challenges. Respirology. 2018;23(4):359-68. 410 
4. Montagnani C, Chiappini E, Galli L, de Martino M. Vaccine against tuberculosis: what’s new? BMC 411 
infectious diseases. 2014;14(1):S2. 412 
5. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. The Lancet. 413 
1995;346(8986):1339-45. 414 
6. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. 415 
Tuberculosis. 2003;83(1-3):91-7. 416 
7. Daffé M, Draper P. The envelope layers of mycobacteria with reference to their pathogenicity.  Advances in 417 
microbial physiology. 39: Elsevier; 1997. p. 131-203. 418 
8. Morandi M, Sali M, Manganelli R, Delogu G. Exploiting the mycobacterial cell wall to design improved 419 
vaccines against tuberculosis. The Journal of Infection in Developing Countries. 2013;7(03):169-81. 420 
9. Kaur D, Guerin ME, Škovierová H, Brennan PJ, Jackson M. Biogenesis of the cell wall and other 421 















10. MINNIKIN DE. Complex lipids, their chemistry biosynthesis and roles. The biology of mycobacteria. 423 
1982;1:95-184. 424 
11. Daffé M. 1 The Global Architecture of the Mycobacterial Cell Envelope.  The mycobacterial cell envelope: 425 
American Society of Microbiology; 2008. p. 3-11. 426 
12. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annual review of biochemistry. 1995;64(1):29-63. 427 
13. Yuan Y, Lee RE, Besra GS, Belisle JT, Barry C. Identification of a gene involved in the biosynthesis of 428 
cyclopropanated mycolic acids in Mycobacterium tuberculosis. Proceedings of the National Academy of 429 
Sciences. 1995;92(14):6630-4. 430 
14. Harland CW, Rabuka D, Bertozzi CR, Parthasarathy R. The Mycobacterium tuberculosis virulence factor 431 
trehalose dimycolate imparts desiccation resistance to model mycobacterial membranes. Biophysical 432 
journal. 2008;94(12):4718-24. 433 
15. Kasmar A, Layre E, Moody B. Lipid adjuvants and antigens embedded in the mycobacterial cell envelope. 434 
The Art & Science of Tuberculosis Vaccine Development. 2014:123-49. 435 
16. Daffe M, Etienne G. The capsule of Mycobacterium tuberculosis and its implications for pathogenicity. 436 
Tubercle and lung disease. 1999;79(3):153-69. 437 
17. Stokes RW, Norris-Jones R, Brooks DE, Beveridge TJ, Doxsee D, Thorson LM. The glycan-rich outer layer 438 
of the cell wall of Mycobacterium tuberculosis acts as an antiphagocytic capsule limiting the association of 439 
the bacterium with macrophages. Infection and immunity. 2004;72(10):5676-86. 440 
18. Rousseau C, Neyrolles O, Bordat Y, Giroux S, Sirakova TD, Prevost MC, et al. Deficiency in 441 
mycolipenate‐and mycosanoate‐derived acyltrehaloses enhances early interactions of Mycobacterium 442 
tuberculosis with host cells. Cellular microbiology. 2003;5(6):405-15. 443 
19. Ortalo-Magne A, Andersen ÅB, Daffé M. The outermost capsular arabinomannans and other 444 
mannoconjugates of virulent and avirulent tubercle bacilli. Microbiology. 1996;142(4):927-35. 445 
20. López M, Sly LM, Luu Y, Young D, Cooper H, Reiner NE. The 19-kDa Mycobacterium tuberculosis protein 446 
induces macrophage apoptosis through Toll-like receptor-2. The Journal of Immunology. 447 
2003;170(5):2409-16. 448 
21. Henao-Tamayo M, Junqueira-Kipnis AP, Ordway D, Gonzales-Juarrero M, Stewart GR, Young DB, et al. A 449 
mutant of Mycobacterium tuberculosis lacking the 19-kDa lipoprotein Rv3763 is highly attenuated in vivo 450 
but retains potent vaccinogenic properties. Vaccine. 2007;25(41):7153-9. 451 
22. Babaki MKZ, Soleimanpour S, Rezaee SA. Antigen 85 complex as a powerful Mycobacterium tuberculosis 452 
immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design. Microbial 453 
Pathogenesis. 2017;112:20-9. 454 
23. Mishra AK, Driessen NN, Appelmelk BJ, Besra GS. Lipoarabinomannan and related glycoconjugates: 455 
structure, biogenesis and role in Mycobacterium tuberculosis physiology and host–pathogen interaction. 456 
FEMS microbiology reviews. 2011;35(6):1126-57. 457 
24. Vercellone A, Nigou J, Puzo G. Relationships between the structure and the roles of lipoarabinomannans 458 
and related glycoconjugates in tuberculosis pathogenesis. Front Biosci. 1998;3:e149-e63. 459 
25. Alderwick LJ, Harrison J, Lloyd GS, Birch HL. The Mycobacterial cell wall—Peptidoglycan and 460 















26. Takayama K, Wang C, Besra GS. Pathway to synthesis and processing of mycolic acids in Mycobacterium 462 
tuberculosis. Clinical microbiology reviews. 2005;18(1):81-101. 463 
27. Hunter RL, Olsen MR, Jagannath C, Actor JK. Multiple roles of cord factor in the pathogenesis of primary, 464 
secondary, and cavitary tuberculosis, including a revised description of the pathology of secondary 465 
disease. Annals of Clinical & Laboratory Science. 2006;36(4):371-86. 466 
28. Barry III CE. Interpreting cell wall ‘virulence factors’ of Mycobacterium tuberculosis. Trends in microbiology. 467 
2001;9(5):237-41. 468 
29. Astarie-Dequeker C, Le Guyader L, Malaga W, Seaphanh F-K, Chalut C, Lopez A, et al. Phthiocerol 469 
dimycocerosates of M. tuberculosis participate in macrophage invasion by inducing changes in the 470 
organization of plasma membrane lipids. PLoS pathogens. 2009;5(2):e1000289. 471 
30. Quigley J, Hughitt VK, Velikovsky CA, Mariuzza RA, El-Sayed NM, Briken V. The cell wall lipid PDIM 472 
contributes to phagosomal escape and host cell exit of Mycobacterium tuberculosis. MBio. 473 
2017;8(2):e00148-17. 474 
31. Dhiman N, Verma I, Khuller G. Immunoprophylactic studies on cell wall associated proteins 475 
ofMycobacterium tuberculosis H 37 Ra. Journal of biosciences. 1997;22(1):13-21. 476 
32. Arora D, Chawla Y, Malakar B, Singh A, Nandicoori VK. The transpeptidase PbpA and non-canonical 477 
transglycosylase RodA of Mycobacterium tuberculosis play important roles in regulating bacterial cell 478 
lengths. Journal of Biological Chemistry. 2018:jbc. M117. 811190. 479 
33. Kieser KJ, Baranowski C, Chao MC, Long JE, Sassetti CM, Waldor MK, et al. Peptidoglycan synthesis in 480 
Mycobacterium tuberculosis is organized into networks with varying drug susceptibility. Proceedings of the 481 
National Academy of Sciences. 2015;112(42):13087-92. 482 
34. Harth G, Horwitz MA. An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selectively 483 
blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: extracellular 484 
proteins as potential novel drug targets. Journal of Experimental Medicine. 1999;189(9):1425-36. 485 
35. Chatterjee D, Bozic C, Knisley C, Cho S, Brennan P. Phenolic glycolipids of Mycobacterium bovis: new 486 
structures and synthesis of a corresponding seroreactive neoglycoprotein. Infection and immunity. 487 
1989;57(2):322-30. 488 
36. Johnson G. The α/β Hydrolase Fold Proteins of Mycobacterium tuberculosis, with Reference to their 489 
Contribution to Virulence. Current Protein and Peptide Science. 2017;18(3):190-210. 490 
37. Crowe AM, Workman SD, Watanabe N, Worrall LJ, Strynadka NC, Eltis LD. IpdAB, a virulence factor in 491 
Mycobacterium tuberculosis, is a cholesterol ring-cleaving hydrolase. Proceedings of the National 492 
Academy of Sciences. 2018;115(15):E3378-E87. 493 
38. Rengarajan J, Bloom BR, Rubin EJ. Genome-wide requirements for Mycobacterium tuberculosis 494 
adaptation and survival in macrophages. Proceedings of the National Academy of Sciences. 495 
2005;102(23):8327-32. 496 
39. Crowe AM, Casabon I, Brown KL, Liu J, Lian J, Rogalski JC, et al. Catabolism of the last two steroid rings 497 
in Mycobacterium tuberculosis and other bacteria. MBio. 2017;8(2):e00321-17. 498 
40. Malm S, Maaß S, Schaible U, Ehlers S, Niemann S. In vivo virulence of Mycobacterium tuberculosis 499 















41. Lentz CS, Ordonez AA, Kasperkiewicz P, La Greca F, O’Donoghue AJ, Schulze CJ, et al. Design of 501 
selective substrates and activity-based probes for Hydrolase Important for Pathogenesis 1 (HIP1) from 502 
Mycobacterium tuberculosis. ACS infectious diseases. 2016;2(11):807-15. 503 
42. Madan-Lala R, Sia JK, King R, Adekambi T, Monin L, Khader SA, et al. Mycobacterium tuberculosis 504 
impairs dendritic cell functions through the serine hydrolase Hip1. The Journal of Immunology. 505 
2014:1303185. 506 
43. Jackson M. The mycobacterial cell envelope—lipids. Cold Spring Harbor perspectives in medicine. 507 
2014:a021105. 508 
44. Maulén NP. Factores de virulencia de Mycobacterium tuberculosis. Revista médica de Chile. 509 
2011;139(12):1605-10. 510 
45. Forrellad MA, Klepp LI, Gioffré A, Sabio y Garcia J, Morbidoni HR, Santangelo MdlP, et al. Virulence 511 
factors of the Mycobacterium tuberculosis complex. Virulence. 2013;4(1):3-66. 512 
46. Rao N, Meena LS. Biosynthesis and virulent behavior of lipids produced by Mycobacterium tuberculosis: 513 
LAM and cord factor: an overview. Biotechnology research international. 2011;2011. 514 
47. Singh P, Rao RN, Reddy JRC, Prasad R, Kotturu SK, Ghosh S, et al. PE11, a PE/PPE family protein of 515 
Mycobacterium tuberculosis is involved in cell wall remodeling and virulence. Scientific reports. 516 
2016;6:21624. 517 
48. Ojha AK, Baughn AD, Sambandan D, Hsu T, Trivelli X, Guerardel Y, et al. Growth of Mycobacterium 518 
tuberculosis biofilms containing free mycolic acids and harbouring drug‐tolerant bacteria. Molecular 519 
microbiology. 2008;69(1):164-74. 520 
49. Vander Beken S, Al Dulayymi JaR, Naessens T, Koza G, Maza‐Iglesias M, Rowles R, et al. Molecular 521 
structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines the elicited 522 
inflammatory pattern. European journal of immunology. 2011;41(2):450-60. 523 
50. Bhatt A, Fujiwara N, Bhatt K, Gurcha SS, Kremer L, Chen B, et al. Deletion of kasB in Mycobacterium 524 
tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. 525 
Proceedings of the National Academy of Sciences. 2007;104(12):5157-62. 526 
51. Guérardel Y, Maes E, Briken V, Chirat F, Leroy Y, Locht C, et al. Lipomannan and lipoarabinomannan from 527 
a clinical isolate of Mycobacterium kansasii novel structural features and apoptosis-inducing properties. 528 
Journal of Biological Chemistry. 2003;278(38):36637-51. 529 
52. Briken V, Porcelli SA, Besra GS, Kremer L. Mycobacterial lipoarabinomannan and related lipoglycans: from 530 
biogenesis to modulation of the immune response. Molecular microbiology. 2004;53(2):391-403. 531 
53. Pathak SK, Basu S, Bhattacharyya A, Pathak S, Kundu M, Basu J. Mycobacterium tuberculosis 532 
lipoarabinomannan-mediated IRAK-M induction negatively regulates Toll-like receptor-dependent 533 
interleukin-12 p40 production in macrophages. Journal of Biological Chemistry. 2005;280(52):42794-800. 534 
54. Nigou J, Zelle-Rieser C, Gilleron M, Thurnher M, Puzo G. Mannosylated lipoarabinomannans inhibit IL-12 535 
production by human dendritic cells: evidence for a negative signal delivered through the mannose 536 
receptor. The Journal of immunology. 2001;166(12):7477-85. 537 
55. Vergne I, Chua J, Lee H-H, Lucas M, Belisle J, Deretic V. Mechanism of phagolysosome biogenesis block 538 
















56. Hunter RL, Hwang S-A, Jagannath C, Actor JK. Cord factor as an invisibility cloak? A hypothesis for 541 
asymptomatic TB persistence. Tuberculosis. 2016;101:S2-S8. 542 
57. Hunter RL, Armitige L, Jagannath C, Actor JK. TB research at UT-Houston–a review of cord factor: new 543 
approaches to drugs, vaccines and the pathogenesis of tuberculosis. Tuberculosis. 2009;89:S18-S25. 544 
58. Silva CL, Faccioli L. Tumor necrosis factor (cachectin) mediates induction of cachexia by cord factor from 545 
mycobacteria. Infection and immunity. 1988;56(12):3067-71. 546 
59. Rao V, Fujiwara N, Porcelli SA, Glickman MS. Mycobacterium tuberculosis controls host innate immune 547 
activation through cyclopropane modification of a glycolipid effector molecule. Journal of experimental 548 
medicine. 2005;201(4):535-43. 549 
60. Reed MB, Domenech P, Manca C, Su H, Barczak AK, Kreiswirth BN, et al. A glycolipid of hypervirulent 550 
tuberculosis strains that inhibits the innate immune response. Nature. 2004;431(7004):84. 551 
61. Goren M, Brennan P. Mycobacterial lipids: chemistry and biologic activities. Tuberculosis. 1979:63-193. 552 
62. Glatman-Freedman A. The role of antibodies against TB. The Art & Science of Tuberculosis Vaccine 553 
Development. 2014:239-73. 554 
63. Teitelbaum R, Glatman-Freedman A, Chen B, Robbins JB, Unanue E, Casadevall A, et al. A mAb 555 
recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proceedings of the 556 
National Academy of Sciences. 1998;95(26):15688-93. 557 
64. Chambers MA, Gavier-Widen D, Glyn Hewinson R. Antibody bound to the surface antigen MPB83 of 558 
Mycobacterium bovis enhances survival against high dose and low dose challenge. FEMS Immunology & 559 
Medical Microbiology. 2004;41(2):93-100. 560 
65. Hamasur B, Haile M, Pawlowski A, Schröder U, Källenius G, Svenson S. A mycobacterial 561 
lipoarabinomannan specific monoclonal antibody and its F (ab′) 2 fragment prolong survival of mice 562 
infected with Mycobacterium tuberculosis. Clinical & Experimental Immunology. 2004;138(1):30-8. 563 
66. Glatman-Freedman A, Mednick AJ, Lendvai N, Casadevall A. Clearance and Organ Distribution 564 
ofMycobacterium tuberculosis Lipoarabinomannan (LAM) in the Presence and Absence of LAM-Binding 565 
Immunoglobulin M. Infection and immunity. 2000;68(1):335-41. 566 
67. Pethe K, Alonso S, Biet F, Delogu G, Brennan MJ, Locht C, et al. The heparin-binding haemagglutinin of 567 
M. tuberculosis is required for extrapulmonary dissemination. Nature. 2001;412(6843):190. 568 
68. Zhang C, Yang L, Zhao N, Zhao Y, Shi C. Insights into Macrophage Autophagy in Latent Tuberculosis 569 
Infection: Role of Heat Shock Protein 16.3. DNA and cell biology. 2018;37(5):442-8. 570 
69. Li F, Kang H, Li J, Zhang D, Zhang Y, Dannenberg Jr A, et al. Subunit Vaccines Consisting of Antigens 571 
from Dormant and Replicating Bacteria Show Promising Therapeutic Effect against Mycobacterium Bovis 572 
BCG Latent Infection. Scandinavian journal of immunology. 2017;85(6):425-32. 573 
70. Singh S, Saraav I, Sharma S. Immunogenic potential of latency associated antigens against 574 
Mycobacterium tuberculosis. Vaccine. 2014;32(6):712-6. 575 
71. Falero-Diaz G, Challacombe S, Rahman D, Mistry M, Douce G, Dougan G, et al. Transmission of IgA and 576 
IgG monoclonal antibodies to mucosal fluids following intranasal or parenteral delivery. International 577 















72. Williams A, Reljic R, Naylor I, Clark SO, Falero‐Diaz G, Singh M, et al. Passive protection with 579 
immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology. 580 
2004;111(3):328-33. 581 
73. López Y, Yero D, Falero-Diaz G, Olivares N, Sarmiento ME, Sifontes S, et al. Induction of a protective 582 
response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16 kDa protein in a model 583 
of progressive pulmonary infection. International Journal of Medical Microbiology. 2009;299(6):447-52. 584 
74. Balu S, Reljic R, Lewis MJ, Pleass RJ, McIntosh R, van Kooten C, et al. A novel human IgA monoclonal 585 
antibody protects against tuberculosis. The Journal of Immunology. 2011:1003189. 586 
75. Alvarez N, Otero O, Camacho F, Borrero R, Tirado Y, Puig A, et al., editors. Passive administration of 587 
purified secretory IgA from human colostrum induces protection against Mycobacterium tuberculosis in a 588 
murine model of progressive pulmonary infection. BMC immunology; 2013: BioMed Central. 589 
76. Olivares N, Puig A, Aguilar D, Moya A, Cádiz A, Otero O, et al. Prophylactic effect of administration of 590 
human gamma globulins in a mouse model of tuberculosis. Tuberculosis. 2009;89(3):218-20. 591 
77. Li H, Wang X-x, Wang B, Fu L, Liu G, Lu Y, et al. Latently and uninfected healthcare workers exposed to 592 
TB make protective antibodies against Mycobacterium tuberculosis. Proceedings of the National Academy 593 
of Sciences. 2017:201611776. 594 
78. Ribi E, Larson C, Wicht W, List R, Goode G. Effective nonliving vaccine against experimental tuberculosis 595 
in mice. Journal of bacteriology. 1966;91(3):975-83. 596 
79. Brehmer W, Anacker RL, Ribi E. Immunogenicity of cell walls from various mycobacteria against airborne 597 
tuberculosis in mice. Journal of bacteriology. 1968;95(6):2000-4. 598 
80. Ribi E, Anacker R, Barclay W, Brehmer W, Harris S, Leif W, et al. Efficacy of mycobacterial cell walls as a 599 
vaccine against airborne tuberculosis in the rhesus monkey. The Journal of infectious diseases. 600 
1971;123(5):527-38. 601 
81. Berinstein A, Piatti P, Gaggino O, Schudel AA, Sadir AM. Enhancement of the immune response elicited 602 
with foot-and-mouth disease virus vaccines by an extract of the Mycobacterium sp. wall. Vaccine. 603 
1991;9(12):883-8. 604 
82. Ivins B, Welkos S, Little S, Crumrine M, Nelson G. Immunization against anthrax with Bacillus anthracis 605 
protective antigen combined with adjuvants. Infection and immunity. 1992;60(2):662-8. 606 
83. Zbar B, Ribj E, Meyer T, Azuma I, Rapp HJ. Immunotherapy of cancer: regression of established 607 
intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets. Journal of 608 
the National Cancer Institute. 1974;52(5):1571-7. 609 
84. Ribi E, Milner KC, Granger DL, Kelly MT, Yamamoto Ki, Brehmer W, et al. Immunotherapy with nonviable 610 
microbial components. Annals of the New York Academy of Sciences. 1976;277(1):228-38. 611 
85. Dascher CC, Hiromatsu K, Xiong X, Morehouse C, Watts G, Liu G, et al. Immunization with a 612 
mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. 613 
International immunology. 2003;15(8):915-25. 614 
86. Rosenkrands I, Agger EM, Olsen AW, Korsholm KS, Andersen CS, Jensen KT, et al. Cationic liposomes 615 
















87. Tima HG, Huygen K, Romano M. Innate signaling by mycobacterial cell wall components and relevance for 618 
development of adjuvants for subunit vaccines. Expert review of vaccines. 2016;15(11):1409-20. 619 
88. Andersen CAS, Rosenkrands I, Olsen AW, Nordly P, Christensen D, Lang R, et al. Novel generation 620 
mycobacterial adjuvant based on liposome-encapsulated monomycoloyl glycerol from Mycobacterium 621 
bovis bacillus Calmette-Guerin. The Journal of Immunology. 2009:jimmunol. 0804091. 622 
89. de Paula L, Silva CL, Carlos D, Matias-Peres C, Sorgi CA, Soares EG, et al. Comparison of different 623 
delivery systems of DNA vaccination for the induction of protection against tuberculosis in mice and guinea 624 
pigs. Genetic vaccines and therapy. 2007;5(1):2. 625 
90. Carlétti D, da Fonseca DM, Gembre AF, Masson AP, Campos LW, Leite LC, et al. A single dose of a DNA 626 
vaccine encoding Apa co-encapsulated with 6, 6’-trehalose dimycolate in microspheres conferred long-627 
term protection against tuberculosis in BCG-primed mice. Clinical and Vaccine Immunology. 2013:CVI. 628 
00148-13. 629 
91. Niu H, Hu L, Li Q, Da Z, Wang B, Tang K, et al. Construction and evaluation of a multistage Mycobacterium 630 
tuberculosis subunit vaccine candidate Mtb10. 4–HspX. Vaccine. 2011;29(51):9451-8. 631 
92. Decout A, Silva-Gomes S, Drocourt D, Barbe S, André I, Cueto FJ, et al. Rational design of adjuvants 632 
targeting the C-type lectin Mincle. Proceedings of the National Academy of Sciences. 2017;114(10):2675-633 
80. 634 
93. Lindenstrøm T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, et al. Tuberculosis subunit 635 
vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. 636 
The Journal of Immunology. 2009;182(12):8047-55. 637 
94. Christensen D, Lindenstrøm T, van de Wijdeven G, Andersen P, Agger EM. Syringe free vaccination with 638 
CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against 639 
tuberculosis. PloS one. 2010;5(11):e15043. 640 
95. Aagaard CS, Hoang TTKT, Vingsbo-Lundberg C, Dietrich J, Andersen P. Quality and vaccine efficacy of 641 
CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium 642 
tuberculosis. The Journal of Immunology. 2009:jimmunol. 0900947. 643 
96. Billeskov R, Tan EV, Cang M, Abalos RM, Burgos J, Pedersen BV, et al. Testing the H56 vaccine delivered 644 
in 4 different adjuvants as a BCG-booster in a non-human primate model of tuberculosis. PLoS One. 645 
2016;11(8):e0161217. 646 
97. Hamasur B, Haile M, Pawlowski A, Schröder U, Williams A, Hatch G, et al. Mycobacterium tuberculosis 647 
arabinomannan–protein conjugates protect against tuberculosis. Vaccine. 2003;21(25-26):4081-93. 648 
98. Haile M, Hamasur B, Jaxmar T, Gavier-Widen D, Chambers M, Sanchez B, et al. Nasal boost with 649 
adjuvanted heat-killed BCG or arabinomannan–protein conjugate improves primary BCG-induced 650 
protection in C57BL/6 mice. Tuberculosis. 2005;85(1-2):107-14. 651 
99. Prados-Rosales R, Carreño L, Cheng T, Blanc C, Weinrick B, Malek A, et al. Enhanced control of 652 
Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate 653 
vaccine. PLoS pathogens. 2017;13(3):e1006250. 654 
100. Parlane NA, Compton BJ, Hayman CM, Painter GF, Basaraba RJ, Heiser A, et al. Phosphatidylinositol di-655 
mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine 656 















101. Larrouy-Maumus G, Layre E, Clark S, Prandi J, Rayner E, Lepore M, et al. Protective efficacy of a lipid 658 
antigen vaccine in a guinea pig model of tuberculosis. Vaccine. 2017;35(10):1395-402. 659 
102. Wedlock DN, Denis M, Painter GF, Ainge GD, Vordermeier HM, Hewinson RG, et al. Enhanced protection 660 
against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial 661 
protein vaccine-adjuvant combination but not after coadministration of adjuvant alone. Clinical and Vaccine 662 
Immunology. 2008;15(5):765-72. 663 
103. Mani R, Gupta M, Malik A, Tandon R, Prasad R, Bhatnagar R, et al. Adjuvant Potential of Poly-α-l-664 
Glutamine from the Cell Wall of Mycobacterium tuberculosis. Infection and immunity. 2018;86(10):e00537-665 
18. 666 
104. Mori L, Lepore M, De Libero G. The immunology of CD1-and MR1-restricted T cells. Annual review of 667 
immunology. 2016;34:479-510. 668 
105. Lepore M, Mori L, De Libero G. The conventional nature of non-MHC-restricted T cells. Frontiers in 669 
immunology. 2018;9. 670 
106. De Libero G, Mori L. The T-cell response to lipid antigens of Mycobacterium tuberculosis. Frontiers in 671 
immunology. 2014;5:219. 672 
107. De Libero G, Singhal A, Lepore M, Mori L. Nonclassical T cells and their antigens in tuberculosis. Cold 673 
Spring Harbor perspectives in medicine. 2014:a018473. 674 
108. Moreno-Mendieta S, Guillén D, Espitia C, Hernández-Pando R, Sanchez S, Rodríguez-Sanoja R. A novel 675 
antigen-carrier system: The Mycobacterium tuberculosis Acr protein carried by raw starch microparticles. 676 
International journal of pharmaceutics. 2014;474(1-2):241-8. 677 
109. Khademi F, Sahebkar A, Fasihi‐Ramandi M, Taheri RA. Induction of strong immune response against a 678 
multicomponent antigen of Mycobacterium tuberculosis in BALB/c mice using PLGA and DOTAP adjuvant. 679 
Apmis. 2018;126(6):509-14. 680 
110. Hovav A-H, Mullerad J, Davidovitch L, Fishman Y, Bigi F, Cataldi A, et al. The Mycobacterium tuberculosis 681 
recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to 682 
protection. Infection and immunity. 2003;71(6):3146-54. 683 
111. Blazevic A, Eickhoff CS, Stanley J, Buller MR, Schriewer J, Kettelson EM, et al. Investigations of TB 684 
vaccine-induced mucosal protection in mice. Microbes and infection. 2014;16(1):73-9. 685 
112. Giri PK, Verma I, Khuller GK. Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 686 
complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal 687 
administration. FEMS Immunology & Medical Microbiology. 2006;47(2):233-41. 688 
113. Sable SB, Verma I, Khuller G. Multicomponent antituberculous subunit vaccine based on immunodominant 689 
antigens of Mycobacterium tuberculosis. Vaccine. 2005;23(32):4175-84. 690 
114. Doherty TM, Olsen AW, van Pinxteren L, Andersen P. Oral vaccination with subunit vaccines protects 691 
animals against aerosol infection with Mycobacterium tuberculosis. Infection and immunity. 692 
2002;70(6):3111-21. 693 
115. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of 694 
Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus 695 















116. Kamath AT, Rochat A-F, Valenti MP, Agger EM, Lingnau K, Andersen P, et al. Adult-like anti-mycobacterial 697 
T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the 698 
IC31® adjuvant. PloS one. 2008;3(11):e3683. 699 
117. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit 700 
vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infection and 701 
immunity. 2004;72(10):6148-50. 702 
118. Langermans JA, Doherty TM, Vervenne RA, van der Laan T, Lyashchenko K, Greenwald R, et al. 703 
Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a 704 
fusion protein of antigen 85B and ESAT-6. Vaccine. 2005;23(21):2740-50. 705 
119. van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, Lingnau K, et al. Ag85B–ESAT-6 adjuvanted with 706 
IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve 707 
human volunteers. Vaccine. 2010;28(20):3571-81. 708 
120. Van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, Bang P, et al. Ag85B–ESAT-6 adjuvanted 709 
with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in 710 
volunteers with previous BCG vaccination or tuberculosis infection. Vaccine. 2011;29(11):2100-9. 711 
121. van Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, et al. A novel liposomal adjuvant 712 
system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. 713 
Vaccine. 2014;32(52):7098-107. 714 
122. Reither K, Katsoulis L, Beattie T, Gardiner N, Lenz N, Said K, et al. Safety and immunogenicity of H1/IC31 715 
(R), an adjuvanted TB subunit vaccine. HIV-infected adults with CD4+ lymphocyte counts greater than. 716 
2014;350:e114602. 717 
123. Mearns H, Geldenhuys HD, Kagina BM, Musvosvi M, Little F, Ratangee F, et al. H1: IC31 vaccination is 718 
safe and induces long-lived TNF-α+ IL-2+ CD4 T cell responses in M. tuberculosis infected and uninfected 719 
adolescents: A randomized trial. Vaccine. 2017;35(1):132-41. 720 
124. Elvang T, Christensen JP, Billeskov R, Hoang TTKT, Holst P, Thomsen AR, et al. CD4 and CD8 T cell 721 
responses to the M. tuberculosis Ag85B-TB10. 4 promoted by adjuvanted subunit, adenovector or 722 
heterologous prime boost vaccination. PloS one. 2009;4(4):e5139. 723 
125. Aagaard C, Hoang TTKT, Izzo A, Billeskov R, Troudt J, Arnett K, et al. Protection and polyfunctional T cells 724 
induced by Ag85B-TB10. 4/IC31® against Mycobacterium tuberculosis is highly dependent on the antigen 725 
dose. PloS one. 2009;4(6):e5930. 726 
126. Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, Goetz MA, et al. Non-clinical efficacy 727 
and safety of HyVac4: IC31 vaccine administered in a BCG prime–boost regimen. Vaccine. 728 
2010;28(4):1084-93. 729 
127. Geldenhuys H, Mearns H, Miles DJ, Tameris M, Hokey D, Shi Z, et al. The tuberculosis vaccine H4: IC31 is 730 
safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized 731 
controlled trial. Vaccine. 2015;33(30):3592-9. 732 
128. Norrby M, Vesikari T, Lindqvist L, Maeurer M, Ahmed R, Mahdavifar S, et al. Safety and immunogenicity of 733 
the novel H4: IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: two phase I dose escalation 734 















129. Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, et al. Prevention of M. tuberculosis 736 
Infection with H4: IC31 Vaccine or BCG Revaccination. New England Journal of Medicine. 737 
2018;379(2):138-49. 738 
130. Aagaard C, Hoang T, Dietrich J, Cardona P-J, Izzo A, Dolganov G, et al. A multistage tuberculosis vaccine 739 
that confers efficient protection before and after exposure. Nature medicine. 2011;17(2):189. 740 
131. Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, Bigbee C, et al. The multistage vaccine H56 boosts the 741 
effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent 742 
Mycobacterium tuberculosis infection. The Journal of clinical investigation. 2012;122(1):303-14. 743 
132. Luabeya AKK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, et al. First-in-human trial of the 744 
post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected 745 
healthy adults. Vaccine. 2015;33(33):4130-40. 746 
133. Billeskov R, Christensen JP, Aagaard C, Andersen P, Dietrich J. Comparing adjuvanted H28 and modified 747 
vaccinia virus ankara expressing H28 in a mouse and a non-human primate tuberculosis model. PloS one. 748 
2013;8(8):e72185. 749 
134. Li Q, Yu H, Zhang Y, Wang B, Jiang W, Da Z, et al. Immunogenicity and protective efficacy of a fusion 750 
protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in 751 
mice. Scandinavian journal of immunology. 2011;73(6):568-76. 752 
135. Luo Y, Wang B, Hu L, Yu H, Da Z, Jiang W, et al. Fusion protein Ag85B-MPT64190–198-Mtb8. 4 has 753 
higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium 754 
tuberculosis in mice. Vaccine. 2009;27(44):6179-85. 755 
136. Chen L, Xu M, Wang Z-Y, Chen B-W, Du W-X, Su C, et al. The development and preliminary evaluation of 756 
a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10: ESAT-6 fusion protein 757 
with CpG DNA and aluminum hydroxide adjuvants. FEMS Immunology & Medical Microbiology. 758 
2010;59(1):42-52. 759 
137. Sable S, Verma I, Behera D, Khuller G. Human immune recognition-based multicomponent subunit 760 
vaccines against tuberculosis. European Respiratory Journal. 2005;25(5):902-10. 761 
138. Teng X, Tian M, Li J, Tan S, Yuan X, Yu Q, et al. Immunogenicity and protective efficacy of DMT liposome-762 
adjuvanted tuberculosis subunit CTT3H vaccine. Human vaccines & immunotherapeutics. 763 
2015;11(6):1456-64. 764 
139. Hogarth PJ, Logan KE, Vordermeier HM, Singh M, Hewinson RG, Chambers MA. Protective immunity 765 
against Mycobacterium bovis induced by vaccination with Rv3109c—a member of the esat-6 gene family. 766 
Vaccine. 2005;23(20):2557-64. 767 
140. Kohama H, Umemura M, Okamoto Y, Yahagi A, Goga H, Harakuni T, et al. Mucosal immunization with 768 
recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of 769 
Mycobacterium bovis bacillus Calmette-Guerin (BCG) in infected mice. Vaccine. 2008;26(7):924-32. 770 
141. Fukui M, Shinjo K, Umemura M, Shigeno S, Harakuni T, Arakawa T, et al. Enhanced effect of BCG vaccine 771 
against pulmonary Mycobacterium tuberculosis infection in mice with lung Th17 response to mycobacterial 772 















142. Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, et al. Differential immune 774 
responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, 775 
delivered as naked DNA or recombinant protein. The Journal of Immunology. 2004;172(12):7618-28. 776 
143. Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC, et al. The protective effect of the 777 
Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 778 
72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infection and immunity. 779 
2004;72(11):6622-32. 780 
144. Tsenova L, Harbacheuski R, Moreira AL, Ellison E, Dalemans W, Alderson MR, et al. Evaluation of the 781 
Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infection and immunity. 782 
2006;74(4):2392-401. 783 
145. Reed SG, Coler RN, Dalemans W, Tan EV, Cruz ECD, Basaraba RJ, et al. Defined tuberculosis vaccine, 784 
Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proceedings of the National Academy of 785 
Sciences. 2009:pnas. 0712077106. 786 
146. Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De Kock E, Pavithran P, et al. The candidate 787 
tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Human vaccines. 788 
2009;5(7):475-82. 789 
147. Spertini F, Audran R, Lurati F, Ofori-Anyinam O, Zysset F, Vandepapelière P, et al. The candidate 790 
tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. 791 
Tuberculosis. 2013;93(2):179-88. 792 
148. Leroux-Roels I, Leroux-Roels G, Ofori-Anyinam O, Moris P, De Kock E, Clement F, et al. Evaluation of the 793 
safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02A candidate tuberculosis 794 
vaccine in purified protein derivative-negative adults. Clinical and Vaccine Immunology. 2010;17(11):1763-795 
71. 796 
149. Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitié M-A, Mettens P, et al. Improved CD4+ T cell 797 
responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the 798 
M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine. 799 
2013;31(17):2196-206. 800 
150. Vipond J, Clark SO, Hatch GJ, Vipond R, Agger EM, Tree JA, et al. Re-formulation of selected DNA 801 
vaccine candidates and their evaluation as protein vaccines using a guinea pig aerosol infection model of 802 
tuberculosis. Tuberculosis. 2006;86(3-4):218-24. 803 
151. Singh A, Khuller G. Induction of immunity against experimental tuberculosis with mycobacterial 804 
mannophosphoinositides encapsulated in liposomes containing lipid A. FEMS Immunology & Medical 805 
Microbiology. 1994;8(2):119-26. 806 
152. Bekierkunst A, Levij I, Yarkoni E, Vilkas E, Adam A, Lederer E. Granuloma formation induced in mice by 807 
chemically defined mycobacterial fractions. Journal of bacteriology. 1969;100(1):95-102. 808 
153. Kato M. Effect of anti-cord factor antibody on experimental tuberculosis in mice. Infection and immunity. 809 
1973;7(1):14-21. 810 
154. Tregoning JS, Kinnear E. Using plasmids as DNA vaccines for infectious diseases.  Plasmids: Biology and 811 















155. Bruffaerts N, Huygen K, Romano M. DNA vaccines against tuberculosis. Expert opinion on biological 813 
therapy. 2014;14(12):1801-13. 814 
156. Yeremeev V, Lyadova I, Nikonenko B, Apt A, Abou‐Zeid C, Inwald J, et al. The 19‐kD antigen and 815 
protective immunity in a murine model of tuberculosis. Clinical & Experimental Immunology. 816 
2000;120(2):274-9. 817 
157. Mollenkopf H-J, Dietrich G, Fensterle J, Grode L, Diehl K-D, Knapp B, et al. Enhanced protective efficacy 818 
of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine. 2004;22(21-819 
22):2690-5. 820 
158. Kirman JR, Turon T, Su H, Li A, Kraus C, Polo JM, et al. Enhanced immunogenicity to Mycobacterium 821 
tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infection and 822 
immunity. 2003;71(1):575-9. 823 
159. Sugawara I, Yamada H, Udagawa T, Huygen K. Vaccination of guinea pigs with DNA encoding Ag85A by 824 
gene gun bombardment. Tuberculosis. 2003;83(6):331-7. 825 
160. Parida SK, Huygen K, Ryffel B, Chakraborty T. Novel bacterial delivery system with attenuated Salmonella 826 
typhimurium carrying plasmid encoding Mtb antigen 85A for mucosal immunization: establishment of proof 827 
of principle in TB mouse model. Annals of the New York Academy of Sciences. 2005;1056(1):366-78. 828 
161. Teixeira FM, Teixeira HC, Ferreira AP, Rodrigues MF, Azevedo V, Macedo GC, et al. DNA vaccine using 829 
Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c 830 
mice. Clinical and vaccine immunology. 2006;13(8):930-5. 831 
162. Feng CG, Palendira U, Demangel C, Spratt JM, Malin S, Britton WJ. Priming by DNA immunization 832 
augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. 833 
Infection and immunity. 2001;69(6):4174-6. 834 
163. Grover A, Ahmed MF, Singh B, Verma I, Sharma P, Khuller G. A multivalent combination of experimental 835 
antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes and infection. 836 
2006;8(9-10):2390-9. 837 
164. Cai H, Yu D, Hu X, Li S, Zhu Y. A combined DNA vaccine-prime, BCG-boost strategy results in better 838 
protection against Mycobacterium bovis challenge. DNA and cell biology. 2006;25(8):438-47. 839 
165. Cai H, Yu D, Tian X, Zhu Y. Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines 840 
significantly enhances the protective efficacy against Mycobacterium tuberculosis. DNA and cell biology. 841 
2005;24(10):605-13. 842 
166. Cai H, Tian X, Hu X, Li S, Yu D, Zhu Y. Combined DNA vaccines formulated either in DDA or in saline 843 
protect cattle from Mycobacterium bovis infection. Vaccine. 2005;23(30):3887-95. 844 
167. Delogu G, Li A, Repique C, Collins F, Morris SL. DNA vaccine combinations expressing either tissue 845 
plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained 846 
protective immunity in a mouse model of pulmonary tuberculosis. Infection and immunity. 2002;70(1):292-847 
302. 848 
168. Skinner MA, Ramsay A, Buchan G, Keen D, Ranasinghe C, Slobbe L, et al. A DNA prime‐live vaccine 849 
boost strategy in mice can augment IFN‐γ responses to mycobacterial antigens but does not increase the 850 
protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis. 851 















169. Derrick SC, Yang AL, Morris SL. A polyvalent DNA vaccine expressing an ESAT6–Ag85B fusion protein 853 
protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced 854 
protective immunity. Vaccine. 2004;23(6):780-8. 855 
170. Chang-hong S, Xiao-wu W, Hai Z, Ting-fen Z, Li-mei W, Zhi-kai X. Immune responses and protective 856 
efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium 857 
tuberculosis. DNA and cell biology. 2008;27(4):199-207. 858 
171. Gao H, Yue Y, Hu L, Xu W, Xiong S. A novel DNA vaccine containing multiple TB-specific epitopes casted 859 
in a natural structure (ECANS) confers protective immunity against pulmonary mycobacterial challenge. 860 
Vaccine. 2009;27(39):5313-9. 861 
172. Cai H, Tian X, Hu X, Zhuang Y, Zhu Y. Combined DNA vaccines formulated in DDA enhance protective 862 
immunity against tuberculosis. DNA and cell biology. 2004;23(7):450-6. 863 
173. Garapin A-C, Ma L, Pescher P, Lagranderie M, Marchal G. Mixed immune response induced in rodents by 864 
two naked DNA genes coding for mycobacterial glycosylated proteins. Vaccine. 2001;19(20-22):2830-41. 865 
174. Dey B, Jain R, Khera A, Rao V, Dhar N, Gupta UD, et al. Boosting with a DNA vaccine expressing ESAT-6 866 
(DNAE6) obliterates the protection imparted by recombinant BCG (rBCGE6) against aerosol 867 
Mycobacterium tuberculosis infection in guinea pigs. Vaccine. 2009;28(1):63-70. 868 
175. Khera A, Singh R, Shakila H, Rao V, Dhar N, Narayanan P, et al. Elicitation of efficient, protective immune 869 
responses by using DNA vaccines against tuberculosis. Vaccine. 2005;23(48-49):5655-65. 870 
176. Maue AC, Waters WR, Palmer MV, Nonnecke BJ, Minion FC, Brown WC, et al. An ESAT-6: CFP10 DNA 871 
vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged 872 
with virulent M. bovis. Vaccine. 2007;25(24):4735-46. 873 
177. Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S. Immunogenicity of DNA vaccines expressing 874 
tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infection and immunity. 875 
1999;67(9):4780-6. 876 
178. Lima K, Dos Santos S, Santos Jr R, Brandao I, Rodrigues Jr J, Silva C. Efficacy of DNA–hsp65 vaccination 877 
for tuberculosis varies with method of DNA introduction in vivo. Vaccine. 2003;22(1):49-56. 878 
179. Gonçalves ED, Bonato VLD, da Fonseca DM, Soares EG, Brandão IT, Soares APM, et al. Improve 879 
protective efficacy of a TB DNA-HSP65 vaccine by BCG priming. Genetic Vaccines and Therapy. 880 
2007;5(1):7. 881 
180. Hogarth PJ, Logan KE, Ferraz JC, Hewinson RG, Chambers MA. Protective efficacy induced by 882 
Mycobacterium bovis bacille Calmette-Guerin can be augmented in an antigen independent manner by use 883 
of non-coding plasmid DNA. Vaccine. 2006;24(1):95-101. 884 
181. Lefèvre P, Denis O, De Wit L, Tanghe A, Vandenbussche P, Content J, et al. Cloning of the Gene 885 
Encoding a 22-Kilodalton Cell Surface Antigen of Mycobacterium bovisBCG and Analysis of Its Potential 886 
for DNA Vaccination against Tuberculosis. Infection and immunity. 2000;68(3):1040-7. 887 
182. Delogu G, Howard A, Collins FM, Morris SL. DNA vaccination against tuberculosis: expression of a 888 
















183. Chambers M, Vordermeier H-M, Whelan A, Commander N, Tascon R, Lowrie D, et al. Vaccination of mice 891 
and cattle with plasmid DNA encoding the Mycobacterium bovis antigen MPB83. Clinical infectious 892 
diseases. 2000;30(Supplement_3):S283-S7. 893 
184. Wedlock D, Skinner M, Parlane N, Vordermeier H, Hewinson R, De Lisle G, et al. Vaccination with DNA 894 
vaccines encoding MPB70 or MPB83 or a MPB70 DNA prime-protein boost does not protect cattle against 895 
bovine tuberculosis. Tuberculosis. 2003;83(6):339-49. 896 
185. Tanghe A, Lefèvre P, Denis O, D’Souza S, Braibant M, Lozes E, et al. Immunogenicity and protective 897 
efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. The Journal of 898 
Immunology. 1999;162(2):1113-9. 899 
186. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: 900 
deployment in sight. Current opinion in immunology. 2011;23(3):377-82. 901 
187. Silva AJd, Zangirolami TC, Novo-Mansur MTM, Giordano RdC, Martins EAL. Live bacterial vaccine 902 
vectors: an overview. Brazilian Journal of Microbiology. 2014;45(4):1117-29. 903 
188. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, et al. Single mucosal, but not 904 
parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from 905 
pulmonary tuberculosis. The Journal of Immunology. 2004;173(10):6357-65. 906 
189. Stylianou E, Griffiths K, Poyntz H, Harrington-Kandt R, Dicks M, Stockdale L, et al. Improvement of BCG 907 
protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both 908 
expressing Ag85A. Vaccine. 2015;33(48):6800-8. 909 
190. Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-910 
vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization 911 
against pulmonary tuberculosis. Infection and immunity. 2006;74(8):4634-43. 912 
191. Santosuosso M, Zhang X, McCormick S, Wang J, Hitt M, Xing Z. Mechanisms of mucosal and parenteral 913 
tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained 914 
accumulation of immune protective CD4 and CD8 T cells within the airway lumen. The Journal of 915 
Immunology. 2005;174(12):7986-94. 916 
192. Xing Z, McFarland CT, Sallenave J-M, Izzo A, Wang J, McMurray DN. Intranasal mucosal boosting with an 917 
adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against 918 
pulmonary tuberculosis. PloS one. 2009;4(6):e5856. 919 
193. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, Thacker T, et al. Viral booster 920 
vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infection and 921 
immunity. 2009;77(8):3364-73. 922 
194. Mu J, Jeyanathan M, Small C-L, Zhang X, Roediger E, Feng X, et al. Immunization with a bivalent 923 
adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent 924 
counterpart against pulmonary tuberculosis. Molecular Therapy. 2009;17(6):1093-100. 925 
195. Radošević K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, Gillissen G, et al. Protective immune 926 
responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 927 
T-cell epitope mapping and role of gamma interferon. Infection and immunity. 2007;75(8):4105-15. 928 
196. Dai G, Rady HF, Huang W, Shellito JE, Mason C, Ramsay AJ. Gene-based neonatal immune priming 929 















197. Shi C, Chen L, Chen Z, Zhang Y, Zhou Z, Lu J, et al. Enhanced protection against tuberculosis by 931 
vaccination with recombinant BCG over-expressing HspX protein. Vaccine. 2010;28(32):5237-44. 932 
198. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-933 
vaccination against tuberculosis in a cynomolgus monkey model. Vaccine. 2005;23(17-18):2132-5. 934 
199. Sugawara I, Li Z, Sun L, Udagawa T, Taniyama T. Recombinant BCG Tokyo (Ag85A) protects cynomolgus 935 
monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis. Tuberculosis. 936 
2007;87(6):518-25. 937 
200. Yuan X, Teng X, Jing Y, Ma J, Tian M, Yu Q, et al. A live attenuated BCG vaccine overexpressing 938 
multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis 939 
infection. Applied microbiology and biotechnology. 2015;99(24):10587-95. 940 
201. Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the 941 
current vaccine in the guinea pig model of pulmonary tuberculosis. Infection and immunity. 942 
2003;71(4):1672-9. 943 
202. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, et al. A new recombinant bacille 944 
Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human 945 
volunteers. The Journal of infectious diseases. 2008;198(10):1491-501. 946 
203. Shi C, Wang X, Zhang H, Xu Z, Li Y, Yuan L. Immune responses and protective efficacy induced by 85B 947 
antigen and early secreted antigenic target-6 kDa antigen fusion protein secreted by recombinant bacille 948 
Calmette-Guérin. Acta biochimica et biophysica Sinica. 2007;39(4):290-6. 949 
204. Xu Y, Zhu B, Wang Q, Chen J, Qie Y, Wang J, et al. Recombinant BCG coexpressing Ag85B, ESAT-6 and 950 
mouse-IFN-γ confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice. FEMS 951 
Immunology & Medical Microbiology. 2007;51(3):480-7. 952 
205. Mohamud R, Azlan M, Yero D, Alvarez N, Sarmiento ME, Acosta A, et al., editors. Immunogenicity of 953 
recombinant Mycobacterium bovis bacille Calmette–Guèrin clones expressing T and B cell epitopes of 954 
Mycobacterium tuberculosis antigens. BMC immunology; 2013: BioMed Central. 955 
206. Sali M, Di Sante G, Cascioferro A, Zumbo A, Nicolo C, Dona V, et al. Surface expression of MPT64 as a 956 
fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against 957 
Mycobacterium tuberculosis in mice. Infection and immunity. 2010;78(12):5202-13. 958 
207. Watanabe K, Matsubara A, Kawano M, Mizuno S, Okamura T, Tsujimura Y, et al. Recombinant Ag85B 959 
vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed 960 
Mycobacteria-specific immune responses by intranasal immunization. Vaccine. 2014;32(15):1727-35. 961 
208. Sereinig S, Stukova M, Zabolotnyh N, Ferko B, Kittel C, Romanova J, et al. Influenza virus NS vectors 962 
expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and 963 
protect animals against tuberculosis challenge. Clinical and vaccine immunology. 2006;13(8):898-904. 964 
209. Kadir N-A, Sarmiento ME, Acosta A, Norazmi M-N. Cellular and humoral immunogenicity of recombinant 965 
Mycobacterium smegmatis expressing Ag85B epitopes in mice. International journal of mycobacteriology. 966 
2016;5(1):7-13. 967 
210. Hess J, Grode L, Hellwig J, Conradt P, Gentschev I, Goebel W, et al. Protection against murine 968 
tuberculosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the 30-kDa 969 















211. Mollenkopf H-J, Groine-Triebkorn D, Andersen P, Hess J, Kaufmann SH. Protective efficacy against 971 
tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by 972 
naked DNA. Vaccine. 2001;19(28-29):4028-35. 973 
212. Hall LJ, Clare S, Pickard D, Clark SO, Kelly DL, El Ghany MA, et al. Characterisation of a live Salmonella 974 
vaccine stably expressing the Mycobacterium tuberculosis Ag85B–ESAT6 fusion protein. Vaccine. 975 
2009;27(49):6894-904. 976 
213. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity 977 
and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using 978 
mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. The Journal of 979 
Immunology. 2003;171(3):1602-9. 980 
214. Williams A, Goonetilleke N, McShane H, Clark SO, Hatch G, Gilbert S, et al. Boosting with poxviruses 981 
enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infection and immunity. 982 
2005;73(6):3814-6. 983 
215. White A, Sibley L, Dennis M, Gooch K, Betts G, Edwards N, et al. An evaluation of the safety and 984 
immunogenicity of a candidate TB vaccine, MVA85A, delivered by aerosol to the lungs of macaques. 985 
Clinical and Vaccine Immunology. 2013:CVI. 00690-12. 986 
216. Satti I, Meyer J, Harris SA, Thomas Z-RM, Griffiths K, Antrobus RD, et al. Safety and immunogenicity of a 987 
candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, 988 
double-blind, randomised controlled trial. The Lancet Infectious diseases. 2014;14(10):939-46. 989 
217. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of 990 
MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-991 
controlled phase 2b trial. The Lancet. 2013;381(9871):1021-8. 992 
218. You Q, Jiang C, Wu Y, Yu X, Chen Y, Zhang X, et al. Subcutaneous Administration of Modified Vaccinia 993 
Virus Ankara Expressing an Ag85B‐ESAT6 Fusion Protein, but Not an Adenovirus‐Based Vaccine, 994 
Protects Mice Against Intravenous Challenge with Mycobacterium tuberculosis. Scandinavian journal of 995 
immunology. 2012;75(1):77-84. 996 
219. Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL. Highly persistent and effective 997 
prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based 998 
tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clinical and Vaccine Immunology. 999 
2010;17(5):793-801. 1000 
220. Roediger EK, Kugathasan K, Zhang X, Lichty BD, Xing Z. Heterologous Boosting of Recombinant 1001 
Adenoviral Prime Immunization With a Novel Vesicular Stomatitis Virus–vectored Tuberculosis Vaccine. 1002 
Molecular Therapy. 2008;16(6):1161-9. 1003 
221. Zhang M, Dong C, Xiong S. Heterologous boosting with recombinant VSV-846 in BCG-primed mice 1004 
confers improved protection against Mycobacterium infection. Human vaccines & immunotherapeutics. 1005 
2017;13(4):816-22. 1006 
222. Zhang M, Dong C, Xiong S. Vesicular stomatitis virus-vectored multi-antigen tuberculosis vaccine limits 1007 
bacterial proliferation in mice following a single intranasal dose. Frontiers in cellular and infection 1008 















223. Jeon BY, Kim HJ, Kim SC, Jo EK, Park JK, Paik TH, et al. Protection of Mice against Mycobacterium 1010 
tuberculosis Infection by Immunization with Aqueous Fraction of Triton X‐100‐soluble Cell Wall Proteins. 1011 
Scandinavian journal of immunology. 2008;67(1):18-23. 1012 
224. Chugh I, Khuller G. Immunoprotective behaviour of liposome entrapped cell wall subunit of Mycobacterium 1013 
tuberculosis against experimental tuberculous infection in mice. European Respiratory Journal. 1014 
1993;6(6):811-5. 1015 
225. García MdlA, Borrero R, Lanio ME, Tirado Y, Alvarez N, Puig A, et al. Protective effect of a lipid-based 1016 
preparation from Mycobacterium smegmatis in a murine model of progressive pulmonary tuberculosis. 1017 
BioMed research international. 2014;2014. 1018 
226. Guirado E, Gil O, Cáceres N, Singh M, Vilaplana C, Cardona P-J. Induction of a specific strong 1019 
polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in 1020 
murine and guinea pig experimental models of tuberculosis. Clinical and Vaccine Immunology. 1021 
2008;15(8):1229-37. 1022 
227. Vilaplana C, Gil O, Cáceres N, Pinto S, Díaz J, Cardona P-J. Prophylactic effect of a therapeutic vaccine 1023 
against TB based on fragments of Mycobacterium tuberculosis. PloS one. 2011;6(5):e20404. 1024 
228. Vilaplana C, Montané E, Pinto S, Barriocanal A, Domenech G, Torres F, et al. Double-blind, randomized, 1025 
placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI®. Vaccine. 1026 
2010;28(4):1106-16. 1027 
229. Nell AS, D’lom E, Bouic P, Sabaté M, Bosser R, Picas J, et al. Safety, tolerability, and immunogenicity of 1028 
the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients 1029 
with latent tuberculosis infection. PLoS One. 2014;9(2):e89612. 1030 
230. van der Pol L, Stork M, van der Ley P. Outer membrane vesicles as platform vaccine technology. 1031 
Biotechnology journal. 2015;10(11):1689-706. 1032 
231. Acevedo R, Fernandez S, Zayas C, Acosta A, Sarmiento ME, Ferro VA, et al. Bacterial outer membrane 1033 
vesicles and vaccine applications. Frontiers in immunology. 2014;5:121. 1034 
232. Gupta S, Rodriguez GM. Mycobacterial extracellular vesicles and host pathogen interactions. Pathogens 1035 
and disease. 2018;76(4):fty031. 1036 
233. White DW, Elliott SR, Odean E, Bemis LT, Tischler AD. Mycobacterium tuberculosis Pst/SenX3-RegX3 1037 
Regulates Membrane Vesicle Production Independently of ESX-5 Activity. mBio. 2018;9(3):e00778-18. 1038 
234. Prados-Rosales R, Baena A, Martinez LR, Luque-Garcia J, Kalscheuer R, Veeraraghavan U, et al. 1039 
Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent 1040 
manner in mice. The Journal of clinical investigation. 2011;121(4):1471-83. 1041 
235. Prados-Rosales R, Carreño LJ, Batista-Gonzalez A, Baena A, Venkataswamy MM, Xu J, et al. 1042 
Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response 1043 
to surface compartments of Mycobacterium tuberculosis. MBio. 2014;5(5):e01921-14. 1044 
236. Tirado Y, Puig A, Alvarez N, Borrero R, Aguilar A, Camacho F, et al. Protective capacity of 1045 
proteoliposomes from Mycobacterium bovis BCG in a mouse model of tuberculosis. Human vaccines & 1046 















237. Tirado Y, Puig A, Alvarez N, Borrero R, Aguilar A, Camacho F, et al. Mycobacterium smegmatis 1048 
proteoliposome induce protection in a murine progressive pulmonary tuberculosis model. Tuberculosis. 1049 
2016;101:44-8. 1050 
238. Bell C, Smith GT, Sweredoski MJ, Hess S. Characterization of the Mycobacterium tuberculosis proteome 1051 
by liquid chromatography mass spectrometry-based proteomics techniques: a comprehensive resource for 1052 
tuberculosis research. Journal of proteome research. 2011;11(1):119-30. 1053 
239. Wolfe LM, Mahaffey SB, Kruh NA, Dobos KM. Proteomic definition of the cell wall of Mycobacterium 1054 
tuberculosis. Journal of proteome research. 2010;9(11):5816-26. 1055 
240. Mawuenyega KG, Forst CV, Dobos KM, Belisle JT, Chen J, Bradbury EM, et al. Mycobacterium 1056 
tuberculosis functional network analysis by global subcellular protein profiling. Molecular Biology of the cell. 1057 
2005;16(1):396-404. 1058 
241. Pal R, Hameed S, Kumar P, Singh S, Fatima Z. Comparative lipidomics of drug sensitive and resistant 1059 
Mycobacterium tuberculosis reveals altered lipid imprints. 3 Biotech. 2017;7(5):325. 1060 
242. Layre E, Al-Mubarak R, Belisle JT, Moody DB. Mycobacterial lipidomics.  Molecular Genetics of 1061 
Mycobacteria, Second Edition: American Society of Microbiology; 2014. p. 341-60. 1062 
243. Zheng RB, Je ́gouzo SA, Joe M, Bai Y, Tran H-A, Shen K, et al. Insights into interactions of mycobacteria 1063 
with the host innate immune system from a novel array of synthetic mycobacterial glycans. ACS chemical 1064 
biology. 2017;12(12):2990-3002. 1065 
244. Hattori Y, Morita D, Fujiwara N, Mori D, Nakamura T, Harashima H, et al. Glycerol monomycolate is a novel 1066 
ligand for the human, but not mouse macrophage inducible C-type lectin, Mincle. Journal of Biological 1067 
Chemistry. 2014:jbc. M114. 566489. 1068 
245. Mazurek J, Ignatowicz L, Kallenius G, Svenson SB, Pawlowski A, Hamasur B. Divergent effects of 1069 
mycobacterial cell wall glycolipids on maturation and function of human monocyte-derived dendritic cells. 1070 
PLoS One. 2012;7(8):e42515. 1071 
246. Ishikawa E, Mori D, Yamasaki S. Recognition of mycobacterial lipids by immune receptors. Trends in 1072 
immunology. 2017;38(1):66-76. 1073 
247. Singhal A, Mori L, De Libero G. T cell recognition of non-peptidic antigens in infectious diseases. The 1074 
Indian journal of medical research. 2013;138(5):620. 1075 
248. Voss G, Casimiro D, Neyrolles O, Williams A, Kaufmann SH, McShane H, et al. Progress and challenges in 1076 
TB vaccine development. F1000Research. 2018;7. 1077 
249. Chiaradia L, Lefebvre C, Parra J, Marcoux J, Burlet-Schiltz O, Etienne G, et al. Dissecting the 1078 
mycobacterial cell envelope and defining the composition of the native mycomembrane. Scientific reports. 1079 
2017;7(1):12807. 1080 
250. Målen H, Pathak S, Søfteland T, de Souza GA, Wiker HG. Research article Definition of novel cell 1081 





















Subunit VCs developed from Mtb CEC   
Comments 
 
Ref Model Route Adjuvant Prime Boost Challenge Protec 
Y/N 
Proteins 
Ag16kDa Mouse O/IN Starch microparticles VC VCx2 No - H&C-IR (108) 
Ag16kDa-EsxS in PLGA Mouse SC DOTAP VC VC No - H&C-IR  (109) 
Ag27kDa Mouse SC Ribi or DDA BCG VC Mtb-IV N-CFU Strong Th1 
(with BCG/Mtb-Ags) 
(110) 
Ag85A Mouse ID CAF01 or  
TDB synthetic 
analogues+DDA 
VC VCx2 Mtb-IN Y-CFU H&C-IIR. Protec  
(+potent: synthetic analogues) 
(92) 
Ag85B Mouse  IN CPG BCG VC BCG-AER Y-CFU Presence of dendritic in BAL  (111) 
Ag85A-Ag85B Mouse IN/SC DDA VC VC Mtb-IN Y-CFU Mucosal, H&C-IR cells.  (112) 
Ag85A-ESAT6  Mouse SC Synthetic PIM2+oil+ 
water (EmulsigenTM) 
VC VCx2 Mbo-AER Y-CFU H&C-IR (100) 
Ag85A-Ag85B-CFP20.5-
CFP25-CFP32  
Mouse SC DDA-MPL  VC VC Mtb Y-CFU H&C-IR (113) 




Mtb-AER Y-CFU C-IR. Oral: no priming effect. (114) 
Guinea pig MPL, CT, LT  
Mouse SC BCG lipids in cationic 
liposomes 
VC VCx2 Mtb-AER Y-CFU H&C-IR 
LT-Protec>BCG  
(86) 
Mouse  PLG    Y-CFU 
& S 
Protec=BCG (103) 
Mouse IN LTK63 BCG VC Mtb-AER Y-CFU C-IR (115) 
Mouse SC MMG in cationic 
liposomes 
VC VCx2 Mtb-AER Y-CFU Protec=BCG (88) 
Mouse SC CAF01 VC VCx2 Mtb-AER Y-CFU C-IR. LT-Protec.  (93) 
Mouse IM CAF01 & Bioneddles VC VCx2 Mtb-AER Y-CFU C-IR. Protec=BCG (94) 
Mouse- 
Neonatal/adult 
SC IC31 or Alum VC  BCG-IV Y-CFU C-IR.  (116) 
Guinea pig SC DDA-MPL or TDB VC VC Mtb-AER Y-S C-IR.  (117) 
NHP IM DDA-MPL or ASO2A VC  Mtb-IT Y-CFU H&C-IR (118) 
HHA-TST- IM IC31 VC  No - C-IR. AT (119) 
HHA- BCG-Vac IM IC31 VC  No - H&C-IR. AT (120) 
HHA-TST- IM CAF01 VC  No - C-IR. AT (121) 
HHIV-Inf-adult IM IC31 VC  No - Phase II. C-IR (Th1). AT (122) 
HHAd-TST-/+ IM IC31 BCG VC No - Phase II. C-IR. AT (123) 
Ag85B-TB10.4 (H4) 
(Aeras-404) 
Mouse SC CAF01 VC/Ad Ad/VC Mtb-AER Y-CFU C-IR  (124) 
Mouse/ 
Guinea pig 
SC IC31 VC  Mtb-AER Y-CFU Dose dependent induction 
Th1.  
(125) 
Guinea pig SC IC31 BCG VC Mtb-AER Y-CFU C-IR (126) 
HHA- BCG-Vac IM IC31 BCG VC No - C-IR. AS. (127) 
HHA-BCG-Vac IM IC31 BCG VC No - Phase I. C-IR. AS&T. (128) 
HHAd-BCG-
Vac 
IM IC31 BCG BCG/ 
VC 





Mouse SC CAF01 BCG VC Mtb-AER Y-CFU C-IR. Protec  
(pre & post exposure) 
(130) 
NHP IM IC31 BCG VC Mtb-IT Y-S C-IR. Protec  
(pre & post exposure) 
(131) 
NHP IM CAF01, CAF04, 
CAF05, IC31 
BCG VC Mtb-IT Y-S C-IR  (96) 
HHA-TST-/+ IM IC31 BCG VC No - H&C-IT. AS&T. (132) 
Ag85B-Rv2660c-
TB10.4(H28) 
Mouse SC CAF01 VC VC/ 
MVA28 
Mtb-AER Y-CFU C-IR. Protec>BCG  
(VC7VC)  
(133) 
NHP IM IC31 BCG VC/ 
MVA28 
Mtb-AER Y-S C-IR. Protec  
(with both schemes)  
Ag85B-HspX-Mpt64- Mouse SC DDA-BCG PSN BCG VC Mtb-IV Y-CFU H&C-IR. Protec>BCG  
Combined vaccines  
(as BCG-booster)  
(134) 
Ag85B -Mpt64-Mtb8.4 
Mouse SC DDA-PSN VC/ 
BCG 
VCx2 Mtb-IV Y-CFU H&C-IR. Protec>BCG  




Mouse SC CpG/Alum VC VCx2 No - H&C-IR (136) 
Guinea pig IM CpG/Alum BCG VCx2 Mtb-SC Y-CFU - 
CFP8-CFP10-CFP15 
ESAT6-TB10.4 
Mouse SC MPL/DDA VC VCx2 Mtb-IV Y-CFU - (137) 
CFP11-CFP21-CFP22.5-
CFP31-MPT64 
















ESAT6 Mouse  SC CAF01 VC VCx2 Mtb-AER Y-CFU C-IR. LT-Protec  
(subdominant epitopes) 
(95) 
EsxR  Mouse SC MPL-TDM  BCG VC Mbo Y-CFU C-IR (139) 
HBHA Mouse IN CT VC VC BCG-IN Y-CFU H&C-IR. (140) 
BCG/ 
VC 
VCx4 Mtb-IT Y-CFU H&C-IR. Protec>BCG 
(as BCG-booster)  
(141) 
Mtb10.4-HspX Mouse SC TDM+DDA BCG VCx2 Mtb-IV Y-CFU Protec=BCG. H&C-IR (91) 
Mtb72F Mouse IM ASO2A/ ASO1B VC VCx2 Mtb-AER Y-CFU H&C-IR (142) 
Mouse/ 
Guinea pig 
SC  ASO2A VC/ 
BCG 
VCx2 Mtb-AER Y-S H&C-IR (143) 




Y-CFU H&C-IR.  (144) 
NHP IM ASO2A BCG/ 
VC 
VCx2/3 Mtb-IT Y-CFU 
& S 
C-IR. Protec>BCG (145) 
HHA-TST- IM ASO2A VC VCx2 No - Phase I. H&C-IR. AT (146) 
HHA-BCG-Vac/ 
Mtb infected 
IM  ASO2A VC VCx2 No - Phase I/II. H&C-IR. AT (147) 
HHA-TST- 
No-BCG-Vac 
IM ASO2A VC VCx3 No - Phase I. H&C-IR. AT (148) 
HHA-TST- IM  ASO1/AS02  VC (M72/ 
M72F) 
VC  No - Phase I/II. H&C-IR. 
Protec>BCG (M72-ASO1). AT 
(149) 
PE20  Guinea pig  IM DDA/TDB VC VCx2 Mtb-AER Y-CFU H&C-IR (150) 
Culture Filtrate Proteins 
(CFPs) 
Cattle SC DDA+MLP or 
synthetic PIM2 or 
Pam3CSK4 with BCG 
VC VCx2 Mbo-IT Y-CFU  Better results with Pam3CSK4  (102) 
Carbohydrates          
AM (Arabinomannan) Mouse SC/IN TT/EurocineTML3 SC  IN  Mtb-IN Y-S C-IR (97) 
Guinea pig SC/IN TT/EurocineTML3 SC  IN  No - H&C-IR 
Mouse  IN TT/EurocineTML3 BCG VC  Mtb-IV Y-CFU C-IR (98) 
AM-Ag85B Mouse SC Alum VC VC  Mtb-IV Y-S - (97) 
Guinea pig SC No SC  IN Mtb-AER Y-CFU 
& S 
- 
Mouse SC Alum VC VCx2 Mtb-AER Y-CFU 
& S 
H-IR Inhibit Mtb dissemination  (99) 
Lipids 
Ac2SGL+ PIM2 (LipVac1) Guinea pig IM DDA & TDB  
(liposomes) 
VC VCx2 Mtb-AER Y-CFU  (101) 
SL37+PIM2 (LipVac2) 
PIMs Mouse  liposomes & lipid A VC  Mtb Y-S H&C-IR (151) 
TDM (cord factor) Mouse  IV/IP  VC VC Mtb-IV Y-S - (152) 




Ac2SGL: Diacylated sulfoglycolipids; AER: aerosol; AM: Arabinomannan; AT: Acceptable tolerability; AS&T: Acceptable Safety & tolerability; BCG: Bacille Calmete-Guerin; 
BCG-Vac: BCG-vaccinated; C cellular; CFU: colony forming unit; HHA: human healthy adults; HHAd: human healthy adolescents; H: humoral; IM: intramuscular;  
IV: intravenous; IT: intratracheal; IP: intraperitoneal; IR: immune response; Inf-adult: infected adults; LT: long term; Mtb: Mycobacterium tuberculosis; M72: point mutation of 
Mtb72F; O: oral; Pam3CSK4: synthetic lipopeptide; PIMs: Mannophosphoinositides; PLG: Poly-α-L-glutamine; Protec: Protection; SC: subcutaneous; S: survival;  





















DNA based VC   
Comments 
 
Ref Model Route Adjuvant Prime Boost  Challenge Protec (Y/N) 
19 kDa /Rv3763 Mouse  IM No VC VCx2 Mtb-IV N H&C-IR (156) 
27kDa Mouse IM No BCG VCx2 Mtb-IV/BCG N -CFU Abrogates BCG Protec  (110) 
Ag85A Mouse IM PLG VC  VCx2 Mtb-AER Y-CFU C-IR (157) 
Mouse  SC No VC VCx2 Mtb-AER Y-CFU C-IR (158) 
Guinea pig GG IFA VC VC/Ag85A Mtb-AER Y-CFU - (159) 
Ag85A (S. thyphimurium as 
delivery system) 
Mouse O/IN No VC VCx2 Mtb-IV Y-CFU H&C-IR (160) 
Ag85B Mouse IM Cardiotoxin VC VCx3 Mbo Y-partial H&C-IR  (161) 
Mouse  IM - VC  VC/BCG Mtb-AER Y-CFU - (162) 
Ag85B-CFP10-CFP21 Mouse  IM No VC VCx2 Mtb-IV Y-CFU H&C-IR.  (163) 
Ag85B-MTP64-MTP83 Cattle c. IM No VC  BCG Mbo Y-CFU C-IR (164) 
Mouse  IM IL2 gene VC  VCx2 Mtb-IV Y-CFU H&C-IR (165) 




Mouse  IM Fused to TPA/ 
ubiquitin-Ub 
VC VCx2 Mtb-AER Y-CFU & S  C-IR (167) 
Ag85A-ESAT6 Mouse  IM No VC VC/BCG/ 
attenuated Mb 
Mbo-AER Y-CFU H&C-IR. Protec=BCG  
(with booster) 
(168) 
Ag85B-ESAT6 Mouse IM No VC/ 
BCG 
VC Mtb-AER Y-CFU & S C-IR-IR. Protec>BCG 
(as booster) 
(169) 
Mouse  IM No VC  VC Mtb Y-CFU H&C-IR. Protec=BCG (170) 
Ag85A-Ag85B-CFP10 ESAT6 
(Tcell epitopes fused to HSP65) 
Mouse 
 
IM No VC VCx3 BCG-IN  Y-CFU H&C-IR (171) 
Ag85B-ESAT6-MPT83 Mouse  IM DDA VC VCx2 Mtb-IV Y-CFU H&C-IR. Protec>BCG (172) 
Apa Mouse  SC/ 
IM 
TDM+PLGA BCG-SC VC-IM Mtb-IT Y-CFU Protec>BCG (90) 




VC VC BCG-IV Y-CFU H&C-IR (173) 
Guinea pig ID  VC - No - H&C-IR 
ESAT6 Mouse IM No VC/rBCG VC/VCx2  No - C-IR (174) 
Guinea pig IM No VC/rBCG VC/VCx2 Mtb-AER N-CFU No protec: VC.  
Abrogates protec  
(as booster of rBCG) 
ESAT6/16kDa/SodA Mouse  IM No VC VCx2 No - H&C-IR (175) 
Guinea pig IM No VC VCx2 Mtb-SC Y-CFU 
ESAT6-CFP10  Bull calves  IM IFA + 
DNA:GM-CSF + 
DNA:CD80/CD86 




Calves IM VC/BCG 
VC+BCG 
VC Mbo-AER Y-CFU Best results with: 
BCG+VC+DNA:GM-CSF+ 
DNA:CD80-CD86) 





No VC VCx2 Mtb-IT Y-CFU H&C-IR. Protec:Y (IM): 




IM TDM+PLGA VC - Mtb-IT Y-CFU H&C-IR. Protec=BCG (89) 
Mouse  IN/IM No  BCG-
IN/SC 
VCx2 Mtb-IT Y-CFU C-IR. Protec>BCG 
(BCG-IN + VC) 
(179) 
Hsp65-Hsp70-Apa Mouse  IM No VC  VCx3/BCG Mbo-IV Y-CFU C-IR. Protec:  
(with BCG boost) 
(180) 
LppX (22kDa) Mouse IM No VC VCx2 Mtb-IV N-CFU H&C-IR (181) 
MPT64 fused to ubiquitin Mouse  IM No VC VCx2 Mtb-AER Y-CFU H&C-IR (182) 
MPB83  Mouse IM No VC VCx3 Mbo-IV Y-CFU H&C-IR (183) 
Cattle c. IM No VC VCx2 No -  C-IR  
MPB70/MPB83 Cattle  IM No VC  VCx2/ 
Proteinx2 
Mbo-IT N-CFU H&C-IR  
(after priming with protein) 
(184) 
Mtb72F Mouse IM No VC VCx2 Mtb-AER Y-CFU H&C-IR (142) 
Guinea pig IM No VC VCx2 Mtb-AER Y-S - 
PstS1/PstS2/PstS3 Mouse IM No VC VCx2 Mtb-IV Y-CFU  H&C-IR. Protec (PstS3) (185) 
 
AER: aerosol; BCG: Bacille Calmete-Guerin; Cattle c.: Cattle calves C cellular; CFU: colony forming unit; GG: Gene-gun; H: humoral; ID: intradermal; IFA: incomplete Freund adjuvant; 
IM: intramuscular; IN: intranasal; IR: immune response; IT: intratracheal; IV: intravenous; Mbo: Mycobacterium bovis Mtb: Mycobacterium tuberculosis; O: oral; Protec: Protection;  




















Mtb CE antigens expressed in attenuated vectors   
Comments 
 
Ref Model Route Prime Boost  Challenge Protec (Y/N) 
Adenovirus (Ad) 
Ag85A Mouse  IM/IN VC-IM/IN VCx2-IM/IN Mtb-IN Y-CFU C-IR. Protec: IN  (188) 
VC-IM/IN VCx3= 2:IM; 1:IN/IM Mtb-IN Y-CFU Protec: IN+IM better results 
Mouse  IN/ID BCG- ChAd-MVA Mtb-AER Y-CFU Protec: ChAd (IN)  
followed by MVA (ID/IN) 
(189) 
Mouse  SC/IN BCG VCx2-IM/IN Mtb-IN Y-CFU C-IR. Protec>BCG: IN (190) 
Mouse IM/IN DNA-IM VC-IN Mtb-IN/AER Y-CFU Protec>BCG: IN (188) 
Mouse/ IM /IN VC - Mtb-IN Y-CFU C-IR. Protec: IN (191) 
Guinea pig IN/IM BCG/VC VC-IN/IM Mtb-AER Y-CFU & S Protec>BCG: IN (192) 
Calves  ID BCG  VC Mbo-IT Y-CFU, 
pathology 
C-IR. Protec>BCG  (193) 
Ag85A-TB10.4 Mouse  IN/IM VC - Mtb-IN Y-CFU C-IR. Protec>BCG (194) 
Ag85A-Ag85B-TB10.4 Mouse IN/IM VC - Mtb-IN Y-CFU C-IR (195) 
Ag85B Mouse  ID/IN DNA-ID VC-IN Mtb-AER Y-CFU C-IR (196) 
BCG 
16kDa Mouse SC VC - Mtb-IV Y-CFU H&C-IR (197) 
72f C. monkey  ID VC VCx2 Mtb-IT Y S C-IR (198) 
Ag85A C. monkey ID VC - Mtb-IT Y-CFU H&C-IR (199) 
Ag85B-16kDa Mouse  SC VC - Mtb-IN Y-CFU H&C-IR (200) 
Ag85B Mouse SC VC - Mtb-IV Y-CFU H&C-IR (197) 
Guinea pig  ID VC - Mtb-AER Y-CFU & S C-IR (201) 
HHA PPD- ID VC - No - C-IR. AT (202) 
Ag85B-ESAT6 Mouse SC VC - Mtb-IV Y-CFU H&C-IR (203) 
Ag85B-ESAT6-INFγ Mouse SC VC - Mtb-IV Y-CFU H&C-IR. Protec>BCG (204) 
Ag85B-CFP10-ESAT6- 
Mtb8.4-MTP40 
Mouse IP VC VCx2  No - H&C-IR (205) 
MPT64-PE_PGRS33 Mouse SC VC - Mtb-AER Y-CFU & S H&C-IR. Protec>BCG  (206) 
Human Parainfluenza type2 virus (rhPIV2) 
Ag85B Mouse  IN VC/DNA VCx3 Mtb-AER Y-CFU C-IR. Protec>BCG (207) 
Influenza virus 
ESAT-6 Mouse/ IN VC VCx2 Mbo-IV Y-CFU C-IR. Protec=BCG (208) 
Guinea pig SC/IN VC VC Mtb-SC Y-CFU Protec=BCG 
Mycobacterium smegmatis 
19 kDa/Rv3763 Mouse SC VC - Mtb-IV N-CFU & S Deleterious effect  (156) 
Ag85B epitope Mouse SC VC VC No - H&C-IR (209) 
Mycobacterium vacae 
19 kDa/Rv3763 Mouse SC VC - Mtb-IV N-CFU & S Deleterious effect (156) 
Salmonella Thyphimurium 
Ag85B  Mouse O/IV VC VCx2  Mtb-IV Y-CFU C-IR (210) 
ESAT6  Mouse IV VC/DNA DNA/VC Mtb-IV Y-CFU C-IR (211) 
Ag85B-ESAT6 Mouse O/IN VC-O/IN Protein-IN No - H&C-IR (212) 
Guinea pig  O/SC VC-O  Protein-SC Mtb-AER Y-CFU & S - 
Modified Vaccinia Virus Ankara (MVA) 
Ag85A Mouse IN/ BCG-IN VC-IN/parenteral Mtb-AER Y-CFU C-IR. Protec>BCG (VC-IN) (213) 
Guinea pig  SC BCG VC/Fowlpox-85A Mtb-AER Y-S Protec>BCG (214) 
Calves  ID BCG  VC Mbo-IT Y-CFU & 
pathology 
C-IR. Protec>BCG  
(VC booster) 
(193) 
R. macaques  ID/AER BCG VC No - IR (AER). AS. (215) 
HHA  ID/AER BCG VC No - Specific-IR. Both were safe  (216) 
HHI ID BCG VC No - C-IR. AS&T. Efficacy=BCG (217) 
Ag85B-ESAT6- Mouse  SC VC - Mtb-IV Y-CFU H&C-IR. Protec>BCG (218) 
Ag85A-Ag85B-ESAT6-
HSP60-MTB39-IL15 




Mtb-IV Y-CFU C-IR (219) 
Vesicular stomatitis virus (VSV) 
Ag85A Mouse  IN/IM VC/Ad VC-IN Mtb-AER Y-CFU C-IR. Protec:  




Mouse IN VC/BCG VC BCG-IN Y-CFU C-IR. Protec>BCG 
(with prime-boost) 
(221) 
VSV-846 Mouse IN VC - BCG-IN Y-CFU C-IR. LT-Protec>BCG  (222) 
 
AER: aerosol; AS: Acceptable safety; AT: Acceptable tolerability; BCG: Bacille Calmete-Guerin; C: cellular; CFU: colony forming unit; ChAd: Chimpanzee Ad; C.monkey: 
Cynomolgus monkey; H: humoral; HHA: human healthy adults; HHI: human healthy infants; ID intradermal; IM: intramuscular; IN: intranasal; IP: intraperitoneal; IR: immune 
response; IT: intratracheal; IV: intravenous; LT: long term; Mbo: Mycobacterium bovis Mtb: Mycobacterium tuberculosis; Protec: Protection; R. macaques: Rhesus macaques; 




















VC based on Mtb CE extracts  
Comments 
 
Ref Model Route Adjuvant Prime Boost  Challenge Protec (Y/N) 
TSP-Aq  Mouse  SC IFA VC VCx2  Mtb-IV Y-CFU C-IR. Protec=BCG  (223) 
CE-PPC Mouse SC/ 
IM 
No VC-SC VCx2- 
SC/IM 
Mtb-IV Y-CFU & S H&C-IR (224) 
LMs  Mouse  SC With/ 
without Alum 
VC VC Mtb-IT Y-CFU Protec= BCG  
(VC with /without Alum) 
(225) 
Myco-CE-O Mouse IV No VC - Mtb-AER Y-CFU Protec: CW from BCG, Mbo, Mtb 
& non-tuberculous mycobacteria  
(78, 79) 
Mtb-WLE Guinea pig  SC QS-21/ 
DDA or both  
VC VCx2 Mtb-AER Y-CFU Protec  
(VC+ QS-21+DDA and QS-21) 
(85) 
RUTI Mouse SC No VC VC Mtb-AER Y-CFU Immunotherapeutic effect on 
reactivation after ST 
chemotherapy. C-IR 
(226) 
Mouse SC No VC VC/ Mtb-AER 
 






VC VC Mtb-AER  - Therapeutic effect  
(decrease of CFU) 
(227) 
Guinea pig SC No VC VC Mtb-AER Y-CFU Immunotherapeutic effect on 
reactivation after ST- 
chemotherapy. 
(226) 
Guinea pig SC No VC VC Mtb-AER N-S - (227) 
HHA-no BCG vac 
Non Mtb infected  
SC No VC VC No - Phase I. C-IR. AT.  (228) 
Latently infected 
HIV (+/-) 
SC No VC VC No - Phase II. C-IR. Reasonable 
tolerability. 
(229) 
Myco-CEO Rhesus Monkey IV No VC - Mtb-AER Y-Chest X-rays & 
gross & microscopic 
pathology  
Protec= BCG  
(CWs from BCG & Mbo)  
(80) 
 
AER: aerosol; AT: Acceptable tolerability; BCG: Bacille Calmete-Guerin; C: cellular; CFU: colony forming unit; CE-PPC: Mtb CE protein peptoglican complex in liposomes;  
H: humoral; HHA: human healthy adults; IFA: Incomplete Freund adjuvant; IM: intramuscular; IR: Immune response; IT: intratracheal; IV: intravenous; LMs: lipid extract from M 
smegmatis; LT: long term; Mbo: Mycobacterium bovis Mtb: Mycobacterium tuberculosis; tb-WLE: Mtb H37Rv-whole lipid extract in liposomes; Myco-CE-O: Mycobacterial-CE 
in oil; Protec: Protection; RUTI Fragmented Mtb cells in liposomes; S: survival; SC: subcutaneous; ST: short term; TSP-Aq: Aqueous fraction of Triton X-1 00-soluble Mtb H37Rv 
















Table 5. Natural and artificial membrane vesicles (MVs) 1098 




Natural and artificial membrane vesicles (MVs)  
Comments 
 




Mouse  SC No VC/ 
BCG 
VC Mtb-AER N/Y  
CFU 
Protec=BCG (MV-Mtb).  
No Protect: (MV-BCG) 
Protec>BCG (as BCG-booster) 
(235) 




VC Mtb-IT Y-CFU Protec=BCG (less lung lesions).  
Protec > BCG (VC as BCG-booster) 
(236) 
PLMs Mouse  SC With/ 
without Alum 
VC VC Mtb-IT Y-CFU Protec (with/without Alum)  
Protec= BCG (VC with Alum)  
(237) 
 
AER: aerosol; BCG: Bacille Calmete-Guerin; CFU: colony forming unit; IT: intratracheal; MV: membrane vesicle; MV-BCG: Natural MV from BCG; MV-Mtb: 
Natural MV from Mycobacterium tuberculosis; PLBCG: Artificial MV from BCG; PLMs: Artificial MV from Mycobacterium smegmatis; Protec: protection;  
SC: subcutaneous; VC: vaccine candidate; Y/N: yes/no 
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